var title_f31_38_32352="Parasternal long view of normal heart";
var content_f31_38_32352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Parasternal long view of normal heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image, obtained using a parasternal long view, shows normal anatomy.",
"    <div class=\"footnotes\">",
"     LV: left ventricle; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32352=[""].join("\n");
var outline_f31_38_32352=null;
var title_f31_38_32353="Eruptive xanthomata forearm";
var content_f31_38_32353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eruptive xanthomata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Xanthomata are seen on the extensor surface of the forearm in a patient with severe hypertriglyceridemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Durrington, P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32353=[""].join("\n");
var outline_f31_38_32353=null;
var title_f31_38_32354="Contact dermatitis (including latex dermatitis)";
var content_f31_38_32354=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Contact dermatitis (including latex dermatitis) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/38/32354/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32354/contributors\" id=\"au5636\">",
"       William L Weston, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32354/contributors\" id=\"au1640\">",
"       William Howe, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/38/32354/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32354/contributors\" id=\"se7157\">",
"       Robert P Dellavalle, MD, PhD, MSPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/38/32354/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32354/contributors\" id=\"de7805\">",
"       Rosamaria Corona, MD, DSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/38/32354?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DERMATITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Dermatitis is defined as an inflammation of the skin. Contact dermatitis refers to dermatitis that is caused by contact between the skin and a substance. The substance can be an allergen (a substance that provokes an allergic reaction) or an irritant (a substance that damages the skin). Irritants are responsible for about 80 percent of cases of contact dermatitis.",
"    </p>",
"    <p>",
"     In most cases, self-care measures and drug therapy can control the symptoms and prevent complications of contact dermatitis.",
"    </p>",
"    <p>",
"     Topic reviews about other skin conditions are also available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/23/15730?source=see_link\">",
"      \"Patient information: Atopic dermatitis (eczema) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/11/3252?source=see_link\">",
"      \"Patient information: Psoriasis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/59/6068?source=see_link\">",
"      \"Patient information: Poison ivy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      IRRITANT CONTACT DERMATITIS",
"     </span>",
"    </p>",
"    <p>",
"     Irritant contact dermatitis occurs when the skin comes in direct contact with a substance that physically, mechanically, or chemically irritates the skin, causing the normal skin barrier to be disrupted.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Cause",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common causes of irritant dermatitis are products used on a daily basis, including soap, cleansers, and rubbing alcohol. People with other skin conditions, dry skin, and light-colored or \"fair\" skin are at greatest risk, although anyone can develop irritant dermatitis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mild irritants cause redness, dryness, fissures (small cracks), and itching. Strong irritants may cause swelling, oozing, tenderness, or blisters (",
"     <a class=\"graphic graphic_picture graphicRef78270 \" href=\"mobipreview.htm?39/11/40112\">",
"      picture 1",
"     </a>",
"     ). The hands are commonly affected, often between the fingers. Irritant dermatitis can also affect the face, especially the thin skin of the eyelids.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The diagnosis of irritant contact dermatitis is usually based upon a person's history and physical examination. In some cases, a patch test (applying a small amount of a substance to the skin) may be recommended to determine if the dermatitis is allergic or irritant-type. Patch testing should be done by a dermatologist or allergist who is trained in this procedure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;The goal of treatment of irritant contact dermatitis is to restore the normal skin barrier and protect the skin from future injury. Reducing exposure to known irritants is essential. In some cases, simply reducing the use of soap and using an emollient cream or ointment completely alleviates symptoms. Wearing gloves when working with irritants may help as well.",
"    </p>",
"    <p>",
"     In more severe cases, topical corticosteroids (steroids) may be recommended. Steroid creams and ointments are available in a variety of strengths (potencies); the least potent are available in the United States without a prescription (eg, hydrocortisone 1% cream). More potent formulations require a prescription.",
"    </p>",
"    <p>",
"     Steroid treatments for contact dermatitis are most effective when applied and covered with a barrier, such as plastic wrap, a dressing (eg, Telfa), cotton gloves, or petroleum jelly. Oral steroids (eg, prednisone) may be used briefly to treat severe dermatitis, but are not recommended for long-term treatment of irritant contact dermatitis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      ALLERGIC CONTACT DERMATITIS",
"     </span>",
"    </p>",
"    <p>",
"     Allergic contact dermatitis occurs when the skin comes in direct contact with an allergen. This activates the body's immune system, which triggers inflammation. Allergic contact dermatitis can occur after being exposed to a new product or after using a product for months or years.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Common allergens",
"     </span>",
"     &nbsp;&mdash;&nbsp;Poison ivy, poison oak, and poison sumac contain an oil called urushiol, which is the most common cause of allergic contact dermatitis. Ginkgo fruit and the skin of mangos also contain urushiol and can cause allergic contact dermatitis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/59/6068?source=see_link\">",
"      \"Patient information: Poison ivy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other common allergens include nickel in jewelry (",
"     <a class=\"graphic graphic_picture graphicRef62784 \" href=\"mobipreview.htm?30/46/31459\">",
"      picture 2",
"     </a>",
"     ), perfumes and cosmetics, components of rubber, nail polish, and chemicals in shoes (both leather and synthetic) (",
"     <a class=\"graphic graphic_picture graphicRef64712 \" href=\"mobipreview.htm?7/30/7663\">",
"      picture 3",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Allergic contact dermatitis can also be triggered by certain medications, including hydrocortisone cream, antibiotic creams (sample brand names: Neosporin&reg;, Bacitracin&reg;), benzocaine, and thimerosal. Laundry detergents are an uncommon cause of allergic contact dermatitis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Symptoms include intense itching and a red raised rash. The rash may blister in severe cases. The rash is usually limited to areas that were in direct contact with the allergen, but a rash can appear in other areas of the body, if the allergen was transferred to those areas on a person's hands (",
"     <a class=\"graphic graphic_picture graphicRef74572 \" href=\"mobipreview.htm?33/54/34670\">",
"      picture 4",
"     </a>",
"     ). Washing the allergen away with soap and water can usually prevent this spread.",
"    </p>",
"    <p>",
"     The rash typically appears within 12 to 48 hours of exposure to the allergen, although in some cases it may not appear for up to two weeks. Less commonly, the rash persists for months or years, which makes it difficult to identify the cause of the reaction.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The diagnosis of allergic contact dermatitis is based upon a person's history and physical examination. If symptoms improve after the allergen is eliminated, this supports the diagnosis. Patch testing may be recommended in some cases and is usually performed by a dermatologist or allergist.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Allergic contact dermatitis usually resolves within two to four weeks after the allergen is eliminated, although it can take more time in some cases. Several measures can minimize symptoms during this time and help to control symptoms in people who have chronic allergic contact dermatitis.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Whenever possible, identify and stop all exposure to the allergen.",
"      </li>",
"      <li>",
"       Oatmeal baths or soothing lotions such as calamine lotion can provide relief in mild cases.",
"      </li>",
"      <li>",
"       Topical corticosteroids (steroids) may be recommended for people with mild to moderate symptoms. Steroid creams and ointments are available in a variety of strengths (potencies); the least potent are available in the United States without a prescription (eg, hydrocortisone 1% cream). More potent formulations require a prescription.",
"      </li>",
"      <li>",
"       For people with more bothersome symptoms, wet or damp dressings are recommended, especially when the affected area is oozing fluid and crusting. Such dressings are soothing and relieve itching, reduce redness, gently remove crusts, and prevent additional injury from scratching.",
"       <br/>",
"       <br/>",
"       A damp cotton garment (the garment is soaked with water and then wrung out) is worn over the affected area and covered with a dry garment. As an example, for an adult with allergic contact dermatitis of the legs, wet long underwear can be covered with larger dry long underwear. Adults may prefer to apply wet dressings at night. When used during the day, wet dressings should be changed every eight hours. Infants and toddlers with extensive skin involvement can wear wet pajamas covered by a dry pair of pajamas or a sleep sack.",
"      </li>",
"      <li>",
"       In people with severe dermatitis, a short course of oral steroids (eg, prednisone) may be recommended to get symptoms under control.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The use of topical antihistamines (sample brand name: Benadryl&reg;) should be avoided because it can cause contact dermatitis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      LATEX DERMATITIS",
"     </span>",
"    </p>",
"    <p>",
"     Latex is a fluid produced by rubber trees that is processed into a variety of products, including gloves, balloons, and condoms. In some individuals, exposure to these products and others (such as rubber bands, erasers, feeding nipples, pacifiers) can cause a contact dermatitis that is either an irritant or allergic reaction. Less commonly, a person can develop a potentially life-threatening allergic reaction to latex.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Irritant dermatitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Irritant dermatitis usually occurs on the hands of people who wear latex or other rubber gloves; the latex acts as an irritant and the gloves trap moisture against the skin. The skin dries out when the gloves are removed, leading to the dermatitis.",
"    </p>",
"    <p>",
"     The symptoms of irritant rubber or latex dermatitis include redness and itching on the skin. There may also be dryness and cracking. Symptoms usually occur within 12 to 36 hours of touching a latex product. Treatment involves avoiding use of any latex-containing products.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Latex allergy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Latex can trigger allergic contact dermatitis. The skin reaction caused by a latex allergy does not differ significantly from that of irritant latex dermatitis.",
"    </p>",
"    <p>",
"     Other manifestations of latex allergy include urticaria (hives) immediately after contact with latex at the site of contact and a severe allergic reaction, which causes swelling, sneezing, and wheezing. Rarely, anaphylaxis can occur, which causes life-threatening difficulty with breathing (see",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=see_link\">",
"      \"Latex allergy: Epidemiology, clinical manifestations, and diagnosis\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;In most cases, the diagnosis of latex allergy is based upon a person's history of exposure.",
"    </p>",
"    <p>",
"     People with a severe latex allergy may immediately develop hives, nasal symptoms, swelling, or wheezing after latex exposure. These individuals may need to see a dermatologist or allergist for specialized skin patch tests and blood testing to verify the latex allergy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;The primary treatment for latex allergy is to avoid all latex-containing products. Non-latex examination gloves are widely available, and use of glove liners may also be an effective approach. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40070?source=see_link\">",
"      \"Latex allergy: Management\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Natural membrane (sometimes called sheep skin) condoms may be used in place of latex condoms, and are effective for preventing pregnancy. However, natural membrane condoms do not protect against sexually transmitted diseases such as HIV, gonorrhea, and chlamydia. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/2/22563?source=see_link\">",
"      \"Patient information: Barrier methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     People with a serious latex allergy should wear a bracelet, necklace, or similar alert tag at all times. If a reaction occurs and the person is too ill to explain their condition, this will help responders provide the proper care as quickly as possible. This measure is especially important in children. The alert tag should include a list of known allergies, as well as the name and phone number of an emergency contact.",
"    </p>",
"    <p>",
"     People with a latex allergy should inform their doctors, dentists, and other healthcare providers about their allergy. Some patients are advised to carry an anaphylaxis kit (containing epinephrine that can be injected under the skin) as a precautionary measure. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=see_link\">",
"      \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498792210\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H185760546\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/53/1874?source=see_link\">",
"      Patient information: Dermatitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/49/43793?source=see_link\">",
"      Patient information: Diaper rash (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/60/5058?source=see_link\">",
"      Patient information: Blisters (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/24/42370?source=see_link\">",
"      Patient information: Allergy skin testing (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H185760554\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/23/15730?source=see_link\">",
"      Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/11/3252?source=see_link\">",
"      Patient information: Psoriasis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/59/6068?source=see_link\">",
"      Patient information: Poison ivy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/2/22563?source=see_link\">",
"      Patient information: Barrier methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=see_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/28/37318?source=see_link\">",
"      Approach to the patient with a scalp eruption",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26104?source=see_link\">",
"      Contact dermatitis in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5336?source=see_link\">",
"      Dermatitis of the vulva",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link\">",
"      Overview of dermatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/44/20168?source=see_link\">",
"      Poison ivy (Toxicodendron) dermatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9785?source=see_link\">",
"      Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40070?source=see_link\">",
"      Latex allergy: Management",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000869.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000869.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Contact Dermatitis Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.contactderm.org/\">",
"      www.contactderm.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Allergy, Asthma and Immunology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aaaai.org/patients/publicedmat/tips/allergicskinconditions.stm\">",
"      www.aaaai.org/patients/publicedmat/tips/allergicskinconditions.stm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?31/38/32354/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/38/32354?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32354/abstract/1\">",
"      Saary J, Qureshi R, Palda V, et al. A systematic review of contact dermatitis treatment and prevention. J Am Acad Dermatol 2005; 53:845.",
"     </a>",
"    </li>",
"    <li>",
"     Sussman G, Gold M. Guidelines for the management of latex allergies and safe latex use in health care facilities. Am College of Allergy Asthma and Immunology. www.acaai.org/public/physicians/latex.htm (Accessed on May 23, 2001).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32354/abstract/3\">",
"      Bourke J, Coulson I, English J, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of contact dermatitis: an update. Br J Dermatol 2009; 160:946.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_38_32354=[""].join("\n");
var outline_f31_38_32354=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DERMATITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           IRRITANT CONTACT DERMATITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           ALLERGIC CONTACT DERMATITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           LATEX DERMATITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/11/40112\" title=\"picture 1\">",
"           Irritant contact derm PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/46/31459\" title=\"picture 2\">",
"           Nickel allergy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/30/7663\" title=\"picture 3\">",
"           Chromate allergy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/54/34670\" title=\"picture 4\">",
"           Allerg contact derm PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_38_32355="Topical cocaine: Patient drug information";
var content_f31_38_32355=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Topical cocaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/54/8038?source=see_link\">",
"     see \"Topical cocaine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/41/35476?source=see_link\">",
"     see \"Topical cocaine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10204387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area of the skin before care.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10204386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cocaine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10204390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10204391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loss of smell.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in taste.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10204393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any pain during care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10204389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10204394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10204395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15549 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32355=[""].join("\n");
var outline_f31_38_32355=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204387\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204386\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204390\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204391\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204393\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204389\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204394\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204395\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/54/8038?source=related_link\">",
"      Topical cocaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/41/35476?source=related_link\">",
"      Topical cocaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_38_32356="Lipoma EUS";
var content_f31_38_32356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Gastrointestinal lipoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endosonographic view of a lipoma. Note the hyperechoic and homogenous character, and originating from the submucosal layer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Lee Krinsky, DO, and Kenneth Binmoeller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32356=[""].join("\n");
var outline_f31_38_32356=null;
var title_f31_38_32357="Prenatal ultrasound ARKPD";
var content_f31_38_32357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69859%7EOBGYN%2F79653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69859%7EOBGYN%2F79653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound ARKPD coronal section",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Autosomal recessive polycystic kidney disease (ARPKD)-Bilateral massively enlarged kidneys with no corticomedullary differentiation. Note associated oligohydramnios.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound of ARPKD transverse section",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Autosomal recessive polycystic kidney disease (ARPKD)-Bilateral massively enlarged kidneys. Ascites is present, but is not a typical feature of this abnormality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32357=[""].join("\n");
var outline_f31_38_32357=null;
var title_f31_38_32358="Mediastinal choriocarcinoma Low";
var content_f31_38_32358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal choriocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Choriocarcinoma is characterized by a dual cell population: mononucleated cytotrophoblastic cells and multinucleated giant syncytio- trophoblastic cells, bordering an area of hemorrhage. (Hematoxylin and eosin, magnification x50).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32358=[""].join("\n");
var outline_f31_38_32358=null;
var title_f31_38_32359="Meropenem: Drug information";
var content_f31_38_32359=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Meropenem: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/47/40691?source=see_link\">",
"    see \"Meropenem: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/24/2439?source=see_link\">",
"    see \"Meropenem: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Merrem&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Merrem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F193364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Carbapenem",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F193326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     I.V.: 1.5-6 g daily divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Extended infusion method (unlabeled dosing):",
"     </i>",
"     I.V.: 0.5-2 g over 3 hours every 8 hours (Crandon, 2011; Dandekar, 2003).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing used at some centers and is based on pharmacokinetic/pharmacodynamic modeling and not clinical efficacy data.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Indication-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Burkholderia pseudomallei",
"      </i>",
"     </b>",
"     <b>",
"      (melioidosis) (unlabeled use),",
"     </b>",
"     <b>",
"      <i>",
"       Pseudomonas:",
"      </i>",
"     </b>",
"     I.V.: 1 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cholangitis, intra-abdominal infections, complicated:",
"     </b>",
"     I.V.: 1 g every 8 hours.",
"     <b>",
"      Note:",
"     </b>",
"     2010 IDSA guidelines recommend  treatment duration of 4-7 days (provided source controlled). Not recommended for mild-to-moderate, community-acquired intra-abdominal infections due to risk of toxicity and the development of resistant organisms (Solomkin, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Febrile neutropenia, otitis externa, pneumonia (unlabeled uses):",
"     </b>",
"     I.V.: 1 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gynecologic and pelvic inflammatory disease:",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     I.V.: 500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Liver abscess (unlabeled use):",
"     </b>",
"     I.V.: 1 g every 8 hours for 2-3 weeks, then oral therapy for duration of 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     I.V.: 2 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mild-to-moderate infection, other severe infections (unlabeled use):",
"     </b>",
"     I.V.: 1.5-3 g daily divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pneumonia (community-acquired):",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     I.V.: 500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pneumonia (nosocomial):",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     I.V.: 1 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prosthetic joint infection,",
"      <i>",
"       Pseudomonas aeruginosa",
"      </i>",
"      (unlabeled use):",
"     </b>",
"     I.V.: 1",
"     <b>",
"      g",
"     </b>",
"     every 8 hours for 4-6 weeks (consider addition of aminoglycoside) (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Septicemia:",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     I.V.: 1 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin and skin structure infections:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Complicated:",
"     </b>",
"     I.V.:  500 mg every 8 hours; diabetic foot: 1 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Uncomplicated:",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     I.V.: 500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Urinary tract infections (complicated):",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     I.V.: 500 mg every 8 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Up to 1 g every 8 hours may be administered (Pallett, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F193345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/24/2439?source=see_link\">",
"      see \"Meropenem: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     Children &ge;3 months: I.V.: 30-120 mg/kg/day divided every 8 hours (maximum dose: 6",
"     <b>",
"      g",
"     </b>",
"     daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Febrile neutropenia (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 months (&lt;50 kg): 20 mg/kg every 8 hours (maximum dose: 1000 mg every 8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;50 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infections (complicated):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 months (&lt;50 kg): 20 mg/kg every 8 hours (maximum dose: 1000 mg every 8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;50 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 months (&lt;50 kg): 40 mg/kg every 8 hours (maximum dose: 2000 mg every 8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;50 kg:",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pneumonia (community-acquired):",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 months (&lt;50 kg): 10-20 mg/kg every 8 hours (maximum dose: 1000 mg every 8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;50 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin and skin structure infections:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Complicated:",
"     </b>",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;3 months (&lt;50 kg): 10 mg/kg every 8 hours (maximum dose: 500 mg every 8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;50 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Uncomplicated:",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S labeling):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;3 months (&lt;50 kg): 10-20 mg/kg every 8 hours (maximum dose: 1000 mg every 8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;50 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infection (complicated):",
"     </b>",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;3 months (&lt;50 kg): 10 mg/kg every 8 hours (maximum dose: 500 mg every 8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;50 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F193327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F193328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       Children",
"      </i>",
"     </b>",
"     (unlabeled dosing; Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GFR 30-50 mL/minute: Administer 20-40 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GFR 10-29 mL/minute: Administer 10-20 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GFR &lt;10 mL/minute: Administer 10-20 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intermittent hemodialysis (IHD): 10-20 mg/kg every 24 hours administer after hemodialysis on dialysis days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peritoneal dialysis (PD): 10-20 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Continuous renal replacement therapy (CRRT): 20-40 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      <i>",
"       Adults:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     26-50 mL/minute: Administer recommended dose based on indication every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-25 mL/minute: Administer one-half recommended dose based on indication every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer one-half recommended dose based on indication every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternative dosing recommendations:",
"     </i>",
"     (unlabeled dosing; Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR 10-50 mL/minute: Administer recommended dose (based on indication) every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR &lt;10 mL/minute: Administer recommended dose (based on indication) every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Meropenem and its metabolite are readily dialyzable: 500 mg every 24 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (unlabeled dose): Administer recommended dose (based on indication) every 24 hours (Aronoff, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH: Loading dose of  1",
"     <b>",
"      g",
"     </b>",
"     followed by either 500 mg every 8 hours",
"     <b>",
"      or",
"     </b>",
"     1000 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHD/CVVHDF: Loading dose of  1",
"     <b>",
"      g",
"     </b>",
"     followed by either 500 mg every 6-8 hours",
"     <b>",
"      or",
"     </b>",
"     1",
"     <b>",
"      g",
"     </b>",
"     every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider giving patients receiving CVVHDF dosages of 750 mg every 8 hours",
"     <b>",
"      or",
"     </b>",
"     1.5",
"     <b>",
"      g",
"     </b>",
"     every 12 hours (Heintz, 2009). Substantial variability exists in various published recommendations, ranging from 1-3",
"     <b>",
"      g",
"     </b>",
"     daily in 2-3 divided doses. One gram every 12 hours achieves a target trough of ~4 mg/L.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg, 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Merrem&reg; I.V.: 500 mg [contains sodium 45.1 mg as sodium carbonate (1.96 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Merrem&reg; I.V.: 1 g [contains sodium 90.2 mg as sodium carbonate (3.92 mEq)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F193302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. infusion over 15-30 minutes; I.V. bolus injection (5-20 mL) over 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended infusion administration (unlabeled dosing): Administer over 3 hours (Crandon 2011; Dandekar, 2003).",
"     <b>",
"      Note:",
"     </b>",
"     Must consider meropenem&rsquo;s limited room temperature stability if using extended infusions",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F193369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS for 4 hours at controlled room temperature and up to 24 hours refrigerated;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, mannitol 2.5%, mannitol 10%, sodium bicarbonate 5%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aminophylline, anidulafungin, atropine, caspofungin, cimetidine, cyclosporine, dexamethasone sodium phosphate, digoxin, diphenhydramine, docetaxel, enalaprilat, fluconazole, furosemide, gentamicin, heparin, insulin (regular), linezolid, metoclopramide, milrinone, morphine, norepinephrine, phenobarbital, telavancin, vancomycin, vasopressin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, diazepam, metronidazole, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, calcium gluconate, doxycycline, ondansetron, potassium chloride, zidovudine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible",
"     </b>",
"     with pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F193301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of intra-abdominal infections (complicated appendicitis and peritonitis); treatment of bacterial meningitis in pediatric patients &ge;3 months of age caused by",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     , and",
"     <i>",
"      N. meningitidis",
"     </i>",
"     ; treatment of complicated skin and skin structure infections caused by susceptible organisms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling: Additional indications (not in U.S. labeling): Treatment of lower respiratory tract infections (community-acquired and nosocomial pneumonias), complicated urinary tract infections, gynecologic infections (excluding chlamydia), and septicemia; treatment of bacterial meningitis in adults caused by",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     , and",
"     <i>",
"      N. meningitidis",
"     </i>",
"     (use in adult meningitis based on pediatric data)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F730176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      Burkholderia pseudomallei",
"     </i>",
"     (melioidosis), febrile neutropenia, liver abscess, otitis externa; treatment of prosthetic joint infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6027563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Meropenem may be confused with ertapenem, imipenem, metroNIDAZOLE",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F193362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 8%), pain (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2% to 3%, includes diaper-area moniliasis in infants), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (4% to 7%), nausea/vomiting (1% to 8%), constipation (1% to 7%), oral moniliasis (up to 2% in pediatric patients), glossitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (&le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Inflammation at the injection site (2%), phlebitis/thrombophlebitis (1%), injection site reaction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Apnea (1%), pharyngitis, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Sepsis (2%), shock (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal enlargement, abdominal pain, agitation/delirium, agranulocytosis, alkaline phosphatase increased, ALT increased, AST increased, anemia (hypochromic), angioedema, anorexia, anxiety, aPTT decreased, asthma, back pain, bilirubin increased, bradycardia, BUN increased, cardiac arrest, chest pain, chills, cholestatic jaundice/jaundice, confusion, cough, creatinine increased, depression, diaphoresis, dizziness, dyspepsia, dyspnea, dysuria, eosinophilia, epistaxis, erythema multiforme, fever, flatulence, gastrointestinal hemorrhage, hallucinations, heart failure, hematuria, hemoglobin/hematocrit decreased, hemolytic anemia, hemoperitoneum, hepatic failure, hyper-/hypotension, hypervolemia, hypokalemia, hypoxia, ileus, injection site edema, injection site pain, insomnia, intestinal obstruction, LDH increased, leukocytosis, leukopenia, melena, MI, nervousness, neutropenia, paresthesia, pelvic pain, peripheral edema, platelets decreased/increased, pleural effusion, PT decreased, pulmonary edema, positive Coombs test, pulmonary embolism, renal failure, respiratory disorder, seizure, skin ulcer, somnolence, Stevens-Johnson syndrome, syncope, tachycardia, toxic epidermal necrolysis, urinary incontinence, urticaria, vaginal moniliasis, weakness, WBC decreased, whole body pain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F193305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to meropenem, any component of the formulation, or other carbapenems (eg, doripenem, ertapenem, imipenem); patients who have experienced anaphylactic reactions to other beta-lactams",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F193287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported (some without a history of previous allergic reactions to beta-lactams).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with moderate-to-severe renal dysfunction. Increased seizure risk and thrombocytopenia have been reported in patients with renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Valproic acid and derivatives: Carbapenems, including meropenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibiotics with divalproex sodium/valproic acid is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional antiseizure medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Lower doses (based upon renal function) are often required in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Carbapenems may decrease the serum concentration of Divalproex.  Management: Concurrent use of carbapenem antibiotics with divalproex is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Meropenem.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Carbapenems may decrease the serum concentration of Valproic Acid.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F193307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Incomplete transplacental transfer of meropenem was found using an",
"     <i>",
"      ex vivo",
"     </i>",
"     human perfusion model.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F193332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excreted in breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3878811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of meropenem are excreted into breast milk (case report). The manufacturer recommends that caution be exercised when administering meropenem to breast-feeding women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F193309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Meropenem Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $18.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $9.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Merrem Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $80.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $40.27",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F193296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perform culture and sensitivity testing prior to initiating therapy. Monitor for signs of anaphylaxis during first dose. During prolonged therapy, monitor renal function, liver function, CBC.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F193310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Caronem (ID);",
"     </li>",
"     <li>",
"      Enem (TH);",
"     </li>",
"     <li>",
"      Eradix (ID);",
"     </li>",
"     <li>",
"      Lanmer (ID);",
"     </li>",
"     <li>",
"      Mabapenem (KP);",
"     </li>",
"     <li>",
"      Mapenem (TH);",
"     </li>",
"     <li>",
"      Mecapem (KP);",
"     </li>",
"     <li>",
"      Meflupin (TW);",
"     </li>",
"     <li>",
"      Melopen (TW);",
"     </li>",
"     <li>",
"      Menem IV (PH);",
"     </li>",
"     <li>",
"      Mepem (CL, TW);",
"     </li>",
"     <li>",
"      Merix (PH);",
"     </li>",
"     <li>",
"      Mero (TH);",
"     </li>",
"     <li>",
"      Merobac I.V. (CO);",
"     </li>",
"     <li>",
"      Merofen (ID);",
"     </li>",
"     <li>",
"      Meromax (PH);",
"     </li>",
"     <li>",
"      Meronem (BB, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, ET, FI, GB, GH, GM, GN, GR, GT, GY, HK, HN, HU, ID, IE, IL, IN, JM, KE, LR, LU, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, NO, PA, PE, PH, PK, PL, PR, PT, RU, SC, SD, SE, SG, SL, SN, SR, SV, TH, TN, TR, TT, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Merop (PH);",
"     </li>",
"     <li>",
"      Meropemed (PE);",
"     </li>",
"     <li>",
"      Meropen (JP, KP, PH);",
"     </li>",
"     <li>",
"      Merosan (ID);",
"     </li>",
"     <li>",
"      Merosin (KP);",
"     </li>",
"     <li>",
"      Meroxi (ID);",
"     </li>",
"     <li>",
"      Merozen (PY);",
"     </li>",
"     <li>",
"      Merrem (AU, IT, MX, NZ);",
"     </li>",
"     <li>",
"      Monem (TH);",
"     </li>",
"     <li>",
"      Myron (TW);",
"     </li>",
"     <li>",
"      Optinem (AT);",
"     </li>",
"     <li>",
"      Romenem (TH);",
"     </li>",
"     <li>",
"      Ronem (ID);",
"     </li>",
"     <li>",
"      Ropen (PH);",
"     </li>",
"     <li>",
"      Tripenem (ID);",
"     </li>",
"     <li>",
"      Zaxter (TH);",
"     </li>",
"     <li>",
"      Zeropenem (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F193286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to several of the penicillin-binding proteins, which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis; bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F193304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 15-20 L, Children: 0.3-0.4 L/kg; penetrates well into most body fluids and tissues; CSF concentrations approximate those of the plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; metabolized to open beta-lactam form (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal renal function: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-80 mL/minute: 1.9-3.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     2-30 mL/minute: 3.82-5.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, tissue: 1 hour following infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~70% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Thoracic Society and Infectious Diseases Society of America, &ldquo;Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2005, 171(4):388-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/15699079/pubmed\" id=\"15699079\" target=\"_blank\">",
"        15699079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 61, 153.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baldwin CM, Lyseng-Williamson KA, and Keam SJ, &ldquo;Meropenem: A Review of Its Use in the Treatment of Serious Bacterial Infections,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2008, 68(6):803-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/18416587/pubmed\" id=\"18416587\" target=\"_blank\">",
"        18416587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blummer JL, Reed MD, Kearns GL, et al, &ldquo;Sequential, Single-Dose Pharmacokinetic Evaluation of Meropenem in Hospitalized Infants and Children,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1995, 39(8):1721-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/7486908/pubmed\" id=\"7486908\" target=\"_blank\">",
"        7486908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley, JS, &ldquo;Meropenem: A New, Extremely Broad Spectrum Beta-lactam Antibiotic for Serious Infections in Pediatrics,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1997, 16:263-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/9076812/pubmed\" id=\"9076812\" target=\"_blank\">",
"        9076812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Craig WA, &ldquo;The Pharmacology of Meropenem, a New Carbapenem Antibiotic,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1997, 24(Suppl 2):266-75.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crandon JL, Ariano RE, Zelenitsky SA, et al, &ldquo;Optimization of Meropenem Dosage in the Critically Ill Population Based on Renal Function,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2011, 37(4):632-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/21136037/pubmed\" id=\"21136037\" target=\"_blank\">",
"        21136037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dandekar PK, Maglio D, Sutherland CA, et al, &ldquo;Pharmacokinetics of Meropenem 0.5 and 2 g Every 8 Hours as a 3-Hour Infusion,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      2003, 23(8):988-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/12921245/pubmed\" id=\"12921245\" target=\"_blank\">",
"        12921245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fish DN and Singletary TJ, &ldquo;Meropenem, A New Carbapenem Antibiotic,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1997, 17(4):644-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/9250544/pubmed\" id=\"9250544\" target=\"_blank\">",
"        9250544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults:  A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2012, 67(2):269-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/22086858/pubmed\" id=\"22086858\" target=\"_blank\">",
"        22086858",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hellinger WC and Brewer NS, &ldquo;Carbapenems and Monobactams: Imipenem, Meropenem, and Aztreonam,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(4):420-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/10221472/pubmed\" id=\"10221472\" target=\"_blank\">",
"        10221472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krueger WA, Schroeder TH, Hutchison M, et al, &ldquo;Pharmacokinetics of Meropenem in Critically Ill Patients With Acute Renal Failure Treated by Continuous Hemodiafiltration,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1998, 42(9):2421-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/9736574/pubmed\" id=\"9736574\" target=\"_blank\">",
"        9736574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linden P, &ldquo;Safety Profile of Meropenem: An Updated Review of Over 6,000 Patients Treated With Meropenem,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2007, 30(8):657-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/17696578/pubmed\" id=\"17696578\" target=\"_blank\">",
"        17696578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ljungberg B and Nilsson-Ehle I, &ldquo;Pharmacokinetics of Meropenem an Its Metabolites in Young and Elderly Healthy Men,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1992, 36(7):1437-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/1510440/pubmed\" id=\"1510440\" target=\"_blank\">",
"        1510440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nicolau DP, &ldquo;Pharmacodynamic Optimization of Beta-lactams in the Patient Care Setting,&rdquo;",
"      <i>",
"       Critical Care",
"      </i>",
"      , 2008, 12(Suppl 4):2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/18495059/pubmed\" id=\"18495059\" target=\"_blank\">",
"        18495059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pallett A and Hand K, &ldquo;Complicated Urinary Tract Infections: Practical Solutions for the Treatment of Multiresistant Gram-Negative Bacteria,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2010, 65(Suppl 3):25-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/20876625/pubmed\" id=\"20876625\" target=\"_blank\">",
"        20876625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ververs TF, van Dijk A, Vinks SA, et al, &ldquo;Pharmacokinetics and Dosing Regimen of Meropenem in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2000, 28(10):3412-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/11057794/pubmed\" id=\"11057794\" target=\"_blank\">",
"        11057794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiseman LR, Wagstaff AJ, Brogden RN, et al, &ldquo;Meropenem. A Review of its Antibacterial Activity, Pharmacokinetic Properties and Clinical Efficacy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1995, 50(1):73-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32359/abstract-text/7588092/pubmed\" id=\"7588092\" target=\"_blank\">",
"        7588092",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9613 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32359=[""].join("\n");
var outline_f31_38_32359=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193322\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193323\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193364\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193326\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193345\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193327\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193328\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193298\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193283\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193302\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193369\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193301\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F730176\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6027563\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193362\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193305\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193287\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299674\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193292\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193294\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193307\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193332\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3878811\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193309\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422265\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193296\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193310\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193286\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193304\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9613\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9613|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/47/40691?source=related_link\">",
"      Meropenem: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/24/2439?source=related_link\">",
"      Meropenem: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_38_32360="Surveillance for metastatic disease after nephrectomy for renal cell carcinoma";
var content_f31_38_32360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surveillance for metastatic disease after nephrectomy for renal cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/38/32360/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32360/contributors\">",
"     Brian Shuch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32360/contributors\">",
"     Allan J Pantuck, MD, MS, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32360/contributors\">",
"     Tobias Klatte, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/38/32360/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32360/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/38/32360/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32360/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/38/32360/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with renal cell carcinoma (RCC), surgery may be curative when patients present with localized disease. However, many patients who are initially resected eventually relapse, and the prognosis in these cases is poor. Thus, optimal management requires careful surveillance for recurrent disease in those who have undergone a potentially curative resection.",
"   </p>",
"   <p>",
"    The timing and patterns of metastatic disease and specific recommendations for surveillance following the initial treatment of localized RCC will be reviewed here. An overview of the treatment of RCC is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages of an aggressive surveillance program must be balanced against the financial costs and the psychologic distress that repeated testing can cause the patient. The rationale for surveillance is based upon several observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis of recurrence while the metastatic burden is limited may increase the likelihood of a favorable response to systemic treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12522?source=see_link&amp;anchor=H2#H2\">",
"       \"Immunotherapy of renal cell carcinoma\", section on 'Interleukin-2'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical resection of a single or limited number of metastases can result in long-term survival. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22630?source=see_link\">",
"       \"Role of surgery in patients with metastatic renal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Early diagnosis of metastasis may minimize complications even if it does not affect survival (eg, prevention of pathologic fractures due to bone metastases).",
"     </li>",
"     <li>",
"      Patients with asymptomatic recurrence detected by surveillance demonstrate improved survival compared to those with symptomatic recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition to concerns about the development of metastatic disease, approximately 3 percent of patients with RCC will develop a second primary renal tumor, with either a synchronous or metachronous presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The important factors in optimizing a surveillance protocol include the time after treatment when metastasis is most likely, the common sites of involvement, and the diagnostic approaches that are most effective in identifying recurrences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TIME TO RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest risk of recurrence following resection of RCC is in the first three to five years. As a result, the primary surveillance efforts focus on this period. However, recurrences can occur even after more than ten years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/3\">",
"     3",
"    </a>",
"    ], and most surveillance protocols are longer than five years.",
"   </p>",
"   <p>",
"    In a series of 2228 patients, the incidence of late renal tumor recurrence (beyond five years) was four percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/4\">",
"     4",
"    </a>",
"    ]. The median time to recurrence among those who relapsed late was nine years (range, five to 25 years) after nephrectomy. On multivariate analysis, the following risk factors were associated with a late recurrence:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor size (one centimeter increase) (hazard ratio [HR] 1.07, 95% CI 1.01-1.14)",
"     </li>",
"     <li>",
"      pT1b (HR 2.81, 95% CI 1.61-4.91)",
"     </li>",
"     <li>",
"      pT2a (HR 4.45, 95% CI 2.34-8.47)",
"     </li>",
"     <li>",
"      pT2b (HR 3.38, 95% CI 1.39-8.23)",
"     </li>",
"     <li>",
"      pT3a-b, pT2c, pT4 (HR 5.09, 95% CI 2.68-9.67)",
"     </li>",
"     <li>",
"      Clear cell histology or collecting duct, NOS (HR 3.76, 95% CI 2.12-6.66)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the increased risk of recurrence with increasing tumor size and stage, the UCLA Integrated Staging System (UISS) has been used to formulate risk-adapted recommendations for surveillance following resection for RCC. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'UISS guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SITES OF METASTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common sites of metastatic disease from RCC are the lungs, bones, liver, renal fossa, and brain, although recurrences may occur elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lung metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung metastases have been reported in 29 to 54 percent of patients with recurrent RCC and are the most common site of metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. When surveillance chest x-rays are performed, more than 90 percent of lung metastases are diagnosed when the patient is asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/5,6,8\">",
"     5,6,8",
"    </a>",
"    ]. Resection of lung metastases in patients without evidence of other disease may result in a five-year survival of up to 33 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All surveillance protocols incorporate periodic imaging of the lungs. The optimal modality remains uncertain, since it is not clear that the increased sensitivity of chest computed tomography (CT) offers additional benefit compared to plain chest x-ray. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Surveillance protocols'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bone metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone metastases have been observed in 16 to 31 percent of patients with recurrent RCC and 67 to 91 percent of those with bone metastasis present with localized pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/5-8,10,11\">",
"     5-8,10,11",
"    </a>",
"    ]. Early identification and treatment of bone metastases can prevent pathologic fractures, minimize pain, and maintain function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recommendations for surveillance in asymptomatic patients have included the use of radionuclide bone scans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/10\">",
"     10",
"    </a>",
"    ] and monitoring serum alkaline phosphatase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/10,14\">",
"     10,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence supporting a benefit from the use of a radionuclide bone scan beyond that of history and physical examination in asymptomatic patients is limited. This was illustrated in a series of 1357 patients with RCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/14\">",
"     14",
"    </a>",
"    ]. Among the 167 cases with bone metastases, 96 percent were symptomatic, with an Eastern Cooperative Oncology Group (ECOG) performance score of 1 or greater (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    ). Among all patients who were asymptomatic (ie, a performance score of 0), only 1.4 percent had bone metastases. The authors concluded that bone scan should be limited to patients with symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, bone scans may be relatively insensitive at detecting the largely lytic metastatic lesions occurring in RCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Alkaline phosphatase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring the serum alkaline phosphatase is simple and inexpensive, but elevated values are seen in only 40 to 55 percent of patients with documented bone metastasis and its specificity is poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. In addition to bone metastases, elevations may be due to liver metastases or a paraneoplastic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\", section on 'Paraneoplastic symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most surveillance strategies to detect bone metastases rely upon the history, physical examination, and measurement of serum alkaline phosphatase. Routine imaging with plain films or bone scan is not recommended, and these tests are reserved to confirm a suspicion of metastasis and to evaluate suspicious findings observed on chest and abdominal scans. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Surveillance protocols'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The general management of bone metastases is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=see_link\">",
"     \"Radiation therapy for the management of painful bone metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22630?source=see_link\">",
"     \"Role of surgery in patients with metastatic renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link\">",
"     \"Psychological, rehabilitative, and integrative therapies for cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Liver metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastases to the liver have been reported in between 8 and 30 percent of patients with recurrent RCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/5-8,14\">",
"     5-8,14",
"    </a>",
"    ]. In about 90 percent of cases, such metastases are detected because of symptoms or abnormal laboratory values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Consequently, all surveillance regimens utilize periodic history, physical examination, and liver function tests to assess for symptoms, hepatomegaly, and laboratory abnormalities.",
"   </p>",
"   <p>",
"    Abdominal CT is the best tool to detect liver metastases, which may be present even in the absence of symptoms or abnormal liver function tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Early detection allows carefully selected patients to undergo local therapies such as radiofrequency ablation, cryotherapy, or metastasectomy, although the evidence supporting the clinical benefit of such an approaches is anecdotal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Surveillance protocols'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22630?source=see_link\">",
"     \"Role of surgery in patients with metastatic renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Local-regional recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local-regional recurrence can result from metastatic disease to the ipsilateral adrenal gland, regional lymph nodes, perirenal fat or Gerota's fascia, or invasion into the psoas muscle. Local recurrence is more common in patients with locally advanced tumors or those with sarcomatoid histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the rate of isolated local recurrence following radical nephrectomy varies with patient selection, such relapses are uncommon. In a series of over 1700 patients from the Mayo Clinic who underwent radical nephrectomy for localized (T1-T3N0M0) RCC (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"mobipreview.htm?14/54/15213\">",
"     table 2",
"    </a>",
"    ), isolated recurrence in the renal fossa was identified in less than 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/17\">",
"     17",
"    </a>",
"    ]. Of these 30 patients with isolated local recurrence, 60 percent were symptomatic and 40 percent were found on routine follow-up evaluation.",
"   </p>",
"   <p>",
"    Early diagnosis of patients with isolated local recurrence is important because surgical resection of such relapses may improve outcome. In the Mayo Clinic experience, there was an actuarial 28 percent five-year survival rate among the patients with isolated renal fossa recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/17\">",
"     17",
"    </a>",
"    ]. In the M. D. Anderson Cancer Center experience, the median survival was five years after resection of isolated local recurrence, with smaller tumor size at recurrence being an important predictor of outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/18\">",
"     18",
"    </a>",
"    ]. Others also have reported anecdotal evidence of prolonged survival following surgical resection in carefully selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the incidence of isolated local recurrence is low, abdominal CT is recommended to simultaneously evaluate for liver metastasis and local recurrence. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Surveillance protocols'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain metastases occur in 2 to 10 percent of patients with recurrent RCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/5-8\">",
"     5-8",
"    </a>",
"    ] and are symptomatic in &ge;80 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/11,17,20,21\">",
"     11,17,20,21",
"    </a>",
"    ]. Affected patients can present with headaches, altered behavior, seizures, or focal neurologic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brain metastases are accompanied by other sites of metastatic disease in most cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. As an example, in a review of 138 patients with brain metastases from RCC seen at UCLA, 95 percent of patients had extracranial sites of metastasis when brain metastasis were diagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/22\">",
"     22",
"    </a>",
"    ]. However, carefully selected patients with good performance statuses and brain metastases can demonstrate long-term survival with aggressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening asymptomatic patients is not recommended given the low incidence of brain metastasis, symptomatic presentation, and frequent association with extracranial sites of metastasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) or CT is reserved for the evaluation of symptomatic patients.",
"   </p>",
"   <p>",
"    An exception to this recommendation against brain surveillance occurs in patients who are being considered for systemic therapy with either interleukin-2 (IL-2) or antiangiogenic agents. IL-2 is associated with increased neurotoxicity, a lowered seizure threshold, and can cause symptomatic perilesional edema in patients with brain metastases, for which IL-2 is ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Antiangiogenic agents may predispose to hemorrhage from CNS lesions.",
"   </p>",
"   <p>",
"    As a result, brain imaging studies (either MRI or CT with contrast) should be performed in patients being considered for IL-2 immunotherapy or antiangiogenic therapy for extracranial metastases. If brain metastases are present, these should be treated prior to systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43064?source=see_link&amp;anchor=H8#H8\">",
"     \"Neurologic complications of cancer treatment with biologic agents\", section on 'Interleukin-2'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SURVEILLANCE PROTOCOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal surveillance protocol presents a challenge in RCC since tumor recurrences have been demonstrated almost everywhere in the body. A comprehensive history and physical examination is the initial step in assessing for signs and symptoms that reflect either systemic disease (eg, weight loss, fever) or specific sites of metastatic involvement. An intensive research effort is currently being focused on identifying blood or urine biomarkers that might enable detection of disease recurrence prior to the appearance of radiologic or clinical symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Extent of primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contemporary surveillance protocols incorporate the extent of the primary RCC at diagnosis in an attempt to increase screening in the patients most like to relapse and to minimize unnecessary testing in those with a better prognosis. Revised recommendations have relied upon the TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"mobipreview.htm?14/54/15213\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical manifestations, evaluation, and staging of renal cell carcinoma\", section on 'TNM staging system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies correlated the extent of the primary tumor (T stage) with the probability of relapse, sites of relapse, and the timing with which metastases appear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     T1 tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of recurrence in patients with T1 RCC lesions is less than 10 percent (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"mobipreview.htm?14/54/15213\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/5,6,8\">",
"     5,6,8",
"    </a>",
"    ]. As a result, recommendations focused on periodic history and physical examination, with chest x-ray and laboratory studies every six months for five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     T2 tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analyses of patients with larger (T2) primary tumors indicate that 16 to 26 percent of cases develop recurrent disease (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"mobipreview.htm?14/54/15213\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/6,8,25\">",
"     6,8,25",
"    </a>",
"    ]. Recommendations were generally similar to those for patients with T1 tumors. Some groups have recommended abdominal CT at year 2 and again at year 4 or 5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/6,26\">",
"     6,26",
"    </a>",
"    ], while others recommended abdominal imaging only when indicated by clinical history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     T3 tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated risk of developing metastatic disease with T3 tumors is 33 to 43 percent at five years (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"mobipreview.htm?14/54/15213\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/6,25\">",
"     6,25",
"    </a>",
"    ]. Follow-up recommendations were similar to those for T2 disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/5,6,8\">",
"     5,6,8",
"    </a>",
"    ], although at least one group recommended increasing the frequency of abdominal CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Histology-based guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patterns of metastatic spread have been analyzed, based upon the histologic subtype of RCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/27\">",
"     27",
"    </a>",
"    ]. In this analysis, clear cell tumors preferentially spread to the lungs, while chromophobe tumors more frequently metastasized to the liver. Based on differential sites of metastasis and time to metastasis, histology-specific protocols have been recommended with differential chest and abdominal imaging surveillance intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3420519\">",
"    <span class=\"h2\">",
"     Integrated staging systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several staging systems have been introduced in order to incorporate numerous clinical and pathologic data variables to better define prognosis for individual patients. The UCLA Integrated Staging System (UISS), Mayo Stage, Size, Necrosis, and Grade system (SSIGN), and the Kattan and the Karakiewicz nomograms have been introduced in the past ten years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/11,29-31\">",
"     11,29-31",
"    </a>",
"    ]. Many of these have been validated in external subsets and their use may allow risk-based surveillance strategies. Many of these systems, however, require detailed pathologic data and may not be able to be used in all cases due to frequent deficiencies in surgical pathologic reporting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/32\">",
"     32",
"    </a>",
"    ]. We prefer the UISS system due to its ease of use and its applicability to all histologic subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     UISS guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UCLA Integrated Staging System (UISS) incorporates the histologic grade of the tumor and the ECOG performance status at the time of diagnosis to further improve on the prognostic information contained in the TNM system. The UISS has been used to formulate recommendations for surveillance following resection for RCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Node-negative patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using the UISS, patients with localized disease without positive lymph nodes (N0M0) are separated into low-, intermediate-, and high-risk groups (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"mobipreview.htm?14/54/15213\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55749 \" href=\"mobipreview.htm?18/56/19341\">",
"     figure 1",
"    </a>",
"    ). This three-tiered system was validated in a multicenter, international study assessing 4202 patients (",
"    <a class=\"graphic graphic_figure graphicRef66352 \" href=\"mobipreview.htm?17/50/18222\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/29\">",
"     29",
"    </a>",
"    ]. Based upon these findings, the following surveillance protocol was proposed (",
"    <a class=\"graphic graphic_figure graphicRef59623 \" href=\"mobipreview.htm?32/7/32895\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For low-risk patients, yearly history, physical examination, laboratory tests, and chest CT for five years, with an abdominal CT at years 2 and 4.",
"     </li>",
"     <li>",
"      For intermediate-risk patients, history, physical examination, laboratory tests, and chest CT every six months for three years and then yearly thereafter for a total follow-up of nine years. Abdominal CT is performed every two years beginning at year 1.",
"     </li>",
"     <li>",
"      In high-risk patients, history, physical examination, laboratory tests, and chest CT every six months for three years and yearly thereafter for a total follow-up of nine years. Abdominal imaging with CT is performed every six months for two years and yearly thereafter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When planning the posttreatment surveillance strategy, care should be taken to limit the number of CT scans if possible, particularly in younger individuals, given concerns about second malignancies induced by radiation exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Node-positive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with regional lymph node involvement (N1 or N2, M0) (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"mobipreview.htm?14/54/15213\">",
"     table 2",
"    </a>",
"    ) have locally advanced, resectable disease without evidence of distant metastases. Although these patients can be stratified into risk groups based upon histologic grade, ECOG-performance score, the extent of nodal disease (N1 or N2), and the presence of metastasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/34\">",
"     34",
"    </a>",
"    ], they are all at high risk for both local and distant disease recurrence.",
"   </p>",
"   <p>",
"    The five-year recurrence-free survival is 36 percent when regional node involvement is present, which is similar to the rate in the high-risk node-negative subset described in the previous section [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast to patients with negative nodes, those with nodal disease often relapse earlier. At three months, chest and abdominal recurrences have been detected in 5 and 10 percent, respectively.",
"   </p>",
"   <p>",
"    Thus, surveillance recommendations for patients with regional lymph node involvement are similar to those for high-risk node-negative disease. Because of the risk of early relapse, the surveillance protocol is instituted at three instead of six months after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     NCCN guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Comprehensive Cancer Network (NCCN) has recommended surveillance guidelines that are based upon the TNM stage at diagnosis (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"mobipreview.htm?14/54/15213\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68636 \" href=\"mobipreview.htm?4/59/5054\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/35\">",
"     35",
"    </a>",
"    ]. These guidelines differ from those of the UISS in the timing and frequency of specific recommendations, and they rely upon chest x-ray rather than CT to monitor for evidence of pulmonary metastases.",
"   </p>",
"   <p>",
"    The NCCN recommendations for patients following resection of stage I and stage II disease can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History, physical examination, chest x-ray, laboratory studies (ie, serum calcium, liver chemistries, LDH, serum creatinine) every six months for the first two years. After two years, these studies are repeated on an annual basis for an additional five years.",
"     </li>",
"     <li>",
"      A single abdominal CT scan is recommended four to six months after surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommendations for patients with resected stage III disease are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History, physical examination, chest x-ray, laboratory studies (ie, serum calcium, liver chemistries, LDH, serum creatinine) every four months for the first two years. These studies are repeated every six months for an additional three years, and annually thereafter.",
"     </li>",
"     <li>",
"      An abdominal CT scan is recommended four to six months after surgery, and annually thereafter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Biomarkers and the future of surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past 10 years, multiple biomarkers have been linked to increased risk of recurrence after nephrectomy.",
"   </p>",
"   <p>",
"    Both UCLA and Mayo groups have developed predictive models that incorporate panels of biomarkers with clinicopathologic information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The addition of these biomarkers appears to improve the predictive capability of these models. Neither model has been externally or prospectively validated, but this concept probably represents the future of prognostication.",
"   </p>",
"   <p>",
"    Challenges to the adoption of these biomarker-based systems will be the variability of tissue preparation, storage, and immunohistochemical scoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Challenges to the adoption of these biomarker-based systems include the variability of tissue preparation and storage, and in interpretation of immunohistochemical scoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/38\">",
"     38",
"    </a>",
"    ]. For these reasons, a cytogenetic approach may be more easily adopted as many centers have facilities capable of performing this technique. Cytogenetic evaluation of renal tumors has been routinely performed at UCLA and assessment of chromosomal alterations can aid in prognostication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32360/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21192?source=see_link&amp;anchor=H7#H7\">",
"     \"Prognostic factors in patients with renal cell carcinoma\", section on 'Molecular markers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3420528\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, no trial has demonstrated efficacy in the adjuvant setting for RCC. Nearly all completed trials, however, took place in the chemotherapy and immunotherapy eras of systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12522?source=see_link&amp;anchor=H34#H34\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Adjuvant immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the development of several active targeted agents for the treatment of metastatic RCC, adjuvant trials have been initiated in patients at high risk of recurrence following initial treatment. Most of these large phase III trials focus on patients with predominantly clear cell histology and are designed to evaluate potential improvement in recurrence-free survival. All but one of these trials are studying the role of receptor tyrosine kinase inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    ); one is testing a chimeric antibody targeting the carbonic anhydrase IX (CAIX) transmembrane protein, which is upregulated in the majority of clear cell RCC due to loss of the VHL protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for surveillance following resection is based upon indirect evidence from patients who are treated for metastatic disease. There are no randomized trials demonstrating increased survival from active surveillance.",
"   </p>",
"   <p>",
"    Following complete resection of renal cell carcinoma (RCC), patients should be monitored for evidence of local recurrence, distant metastasis, or a second primary RCC. Contemporary recommendations for surveillance incorporate information from the TNM staging system along with other key prognostic factors. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Surveillance protocols'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Surveillance protocols focus on the sites most frequently involved with metastases, including the lung, bones, liver, and renal fossa, and match testing with the period of greatest risk of recurrence. These surveillance protocols must be adjusted for the needs of the individual patient, based upon clinical judgment and experience. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Sites of metastasis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Time to recurrence'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Surveillance protocols'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend surveillance for evidence of recurrence after potentially curative surgery for RCC, with the intensity and duration of screening based upon the likelihood of relapse (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We prefer the protocol based upon the UISS risk-stratification system (",
"      <a class=\"graphic graphic_figure graphicRef55749 \" href=\"mobipreview.htm?18/56/19341\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef59623 \" href=\"mobipreview.htm?32/7/32895\">",
"       figure 3",
"      </a>",
"      ), but the National Comprehensive Cancer Network (NCCN) guidelines are a suitable alternative (",
"      <a class=\"graphic graphic_figure graphicRef68636 \" href=\"mobipreview.htm?4/59/5054\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'UISS guidelines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'NCCN guidelines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Based upon the early recurrence pattern and high frequency of pulmonary metastasis, we obtain chest CT scans in order to detect recurrence early. After three years for HR patients alternating chest X-ray with chest CT is acceptable. The NCCN guidelines take a more conservative approach and utilize chest x-ray, rather than CT, to screen for lung metastases.",
"     </li>",
"     <li>",
"      For low-risk, node-negative patients, UISS recommendations include history, physical examination, laboratory tests, and thoracic imaging yearly for five years, and abdominal CT at years 2 and 4.",
"     </li>",
"     <li>",
"      For intermediate-risk, node-negative patients, history, physical examination, laboratory tests, and thoracic imaging are recommended every six months for three years and then yearly for a total follow-up of nine years. Abdominal CT is suggested every two years beginning at year 1. The total follow-up should be nine years.",
"     </li>",
"     <li>",
"      In high-risk, node-negative patients, history, physical examination, laboratory tests, and thoracic imaging are recommended every six months for three years and yearly thereafter for a total follow-up of nine years. Abdominal imaging with CT is recommended every six months for two years and yearly thereafter.",
"     </li>",
"     <li>",
"      Patients with positive regional lymph nodes should be managed like high-risk, node-negative patients, although surveillance should begin at three months, rather than six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      routinely monitoring asymptomatic patients for brain metastases (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with advanced disease being considered for either interleukin-2 (IL-2) immunotherapy or anti-angiogenic therapy should have either MRI or CT prior to treatment of their systemic disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Brain metastases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/1\">",
"      Antonelli A, Cozzoli A, Zani D, et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 2007; 99:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/2\">",
"      Klatte T, Patard JJ, Wunderlich H, et al. Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol 2007; 177:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/3\">",
"      Miyao N, Naito S, Ozono S, et al. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology 2011; 77:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/4\">",
"      Kim SP, Weight CJ, Leibovich BC, et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 2011; 78:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/5\">",
"      Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999; 84:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/6\">",
"      Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/7\">",
"      Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997; 157:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/8\">",
"      Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995; 154:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/9\">",
"      Hofmann HS, Neef H, Krohe K, et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 2005; 48:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/10\">",
"      Seaman E, Goluboff ET, Ross S, Sawczuk IS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology 1996; 48:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/11\">",
"      Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/12\">",
"      Baloch KG, Grimer RJ, Carter SR, Tillman RM. Radical surgery for the solitary bony metastasis from renal-cell carcinoma. J Bone Joint Surg Br 2000; 82:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/13\">",
"      Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol 2000; 164:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/14\">",
"      Shvarts O, Lam JS, Kim HL, et al. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol 2004; 172:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/15\">",
"      Franklin JR, Figlin R, Rauch J, et al. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Semin Urol Oncol 1996; 14:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/16\">",
"      Fujisaki S, Takayama T, Shimada K, et al. Hepatectomy for metastatic renal cell carcinoma. Hepatogastroenterology 1997; 44:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/17\">",
"      Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000; 164:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/18\">",
"      Margulis V, McDonald M, Tamboli P, et al. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol 2009; 181:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/19\">",
"      Sandhu SS, Symes A, A'Hern R, et al. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int 2005; 95:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/20\">",
"      Mori Y, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 1998; 83:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/21\">",
"      Hoshi S, Jokura H, Nakamura H, et al. Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: results in 42 patients. Int J Urol 2002; 9:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/22\">",
"      Shuch B, La Rochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008; 113:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/23\">",
"      Bukowski RM, Young J, Goodman G, et al. Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinoma. Invest New Drugs 1993; 11:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/24\">",
"      Karp BI, Yang JC, Khorsand M, et al. Multiple cerebral lesions complicating therapy with interleukin-2. Neurology 1996; 47:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/25\">",
"      Stephenson AJ, Chetner MP, Rourke K, et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 2004; 172:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/26\">",
"      Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001; 166:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/27\">",
"      Hoffmann NE, Gillett MD, Cheville JC, et al. Differences in organ system of distant metastasis by renal cell carcinoma subtype. J Urol 2008; 179:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/28\">",
"      Siddiqui SA, Frank I, Cheville JC, et al. Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int 2009; 104:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/29\">",
"      Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004; 22:3316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/30\">",
"      Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/31\">",
"      Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/32\">",
"      Shuch B, Pantuck AJ, Pouliot F, et al. Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance. BJU Int 2011; 108:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/33\">",
"      Lam JS, Shvarts O, Leppert JT, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005; 174:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/34\">",
"      Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20:4559.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/36\">",
"      Klatte T, Seligson DB, LaRochelle J, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 2009; 18:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/37\">",
"      Parker AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009; 115:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/38\">",
"      Di Napoli A, Signoretti S. Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer 2009; 115:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32360/abstract/39\">",
"      Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009; 27:746.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2969 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32360=[""].join("\n");
var outline_f31_38_32360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIME TO RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SITES OF METASTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lung metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bone metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Bone scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Alkaline phosphatase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Liver metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Local-regional recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SURVEILLANCE PROTOCOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Extent of primary tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - T1 tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - T2 tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - T3 tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Histology-based guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3420519\">",
"      Integrated staging systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      UISS guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Node-negative patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Node-positive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NCCN guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Biomarkers and the future of surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3420528\">",
"      ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2969\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2969|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/56/19341\" title=\"figure 1\">",
"      N0M0 nephrectomized patie",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/50/18222\" title=\"figure 2\">",
"      Prognosis RCC by UISS stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/7/32895\" title=\"figure 3\">",
"      UISS surveillance protoco",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/59/5054\" title=\"figure 4\">",
"      NCCN recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2969|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/54/15213\" title=\"table 2\">",
"      TNM staging RCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35336?source=related_link\">",
"      Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12522?source=related_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/3/43064?source=related_link\">",
"      Neurologic complications of cancer treatment with biologic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21192?source=related_link\">",
"      Prognostic factors in patients with renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=related_link\">",
"      Psychological, rehabilitative, and integrative therapies for cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22630?source=related_link\">",
"      Role of surgery in patients with metastatic renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_38_32361="Nicardipine: Pediatric drug information";
var content_f31_38_32361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nicardipine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"    see \"Nicardipine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/10/12453?source=see_link\">",
"    see \"Nicardipine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cardene&reg; I.V.;",
"     </li>",
"     <li>",
"      Cardene&reg; SR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1027433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianginal Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker, Dihydropyridine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral and I.V. doses are",
"     <b>",
"      not",
"     </b>",
"     equivalent on a mg per mg basis; limited data available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous I.V. infusion: Initial: 0.5 mcg/kg/minute was used in one prospective, open-label study of 20 hypertensive neonates (15 preterm; median PNA: 15 days). Doses were titrated according to blood pressure; the mean maximal required dose was 0.74 &plusmn; 0.41 mcg/kg/minute (range: 0.5-2 mcg/kg/minute) and occurred at 12 &plusmn; 19 hours of nicardipine infusion. The median duration of treatment was 11 days (range: 2-43 days) (Milou, 2000). Similar doses were required in a smaller study of eight  preterm infants and in one case report of a neonate who received ECMO therapy (Gouyon, 1997; McBride, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1027471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"      see \"Nicardipine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral and I.V. doses are",
"     <b>",
"      not",
"     </b>",
"     equivalent on a mg per mg basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"     <b>",
"      Note:",
"     </b>",
"     Limited information exists; dose is not well established. Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: Some experts recommend the following: Initial: 0.5-1 mcg/kg/minute; titrate dose according to blood pressure; rate of infusion may be increased every 15-30 minutes; maximum dose: 4-5 mcg/kg/minute (Flynn, 2000; Flynn, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In a retrospective analysis of 29 pediatric patients (mean: 7.8 years, range: 2 days to 18 years), an initial dose of 0.5-1 mcg/kg/minute; doses were titrated according to blood pressure and the rate of infusion was increased every 15-30 minutes; the mean effective dose was 1.8 &plusmn; 0.3 mcg/kg/minute (range: 0.3-4 mcg/kg/minute); blood pressure was controlled within 2.7 &plusmn; 2.1 hours (range: 0.5-9 hours) after starting nicardipine continuous infusion (Flynn, 2001). Other smaller studies support the use of an initial pediatric nicardipine dose of 1 mcg/kg/minute (Nakagawa, 2004; Treluyer, 1993). However, several studies used a higher initial dose of 5 mcg/kg/minute; once blood pressure was controlled, the dose was decreased to a lower maintenance dose. Mean maintenance doses have been reported to be 2.4 mcg/kg/minute (range: 1-5 mcg/kg/minute in 10 PICU patients) and 3 mcg/kg/minute (range: 2.1-5.5 mcg/kg/minute in 9 post-op cardiac surgery patients) (Tobias, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: One case report used 20 mg every 8 hours in a 14-year old boy following cardiac transplant (Larsen, 1994). Another case used 30 mg every 8 hours in a 14-year old girl with renal disease (Michael, 1998).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immediate release: Initial: 20 mg 3 times/day; titrate to response; usual: 20-40 mg 3 times/day; allow at least 3 days between increases in dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Sustained release: Initial: 30 mg twice daily; titrate to response; usual: 30-60 mg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Usual dosage range (JNC 7): 30-60 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use caution and re-examine blood pressure control when converting patients from the immediate release to the sustained release product; the total daily dose of immediate release product may not be equivalent to the daily sustained-release dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. continuous infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hypertension in patients",
"     <b>",
"      not",
"     </b>",
"     receiving oral nicardipine: Initial: 5 mg/hour; titrate dose according to blood pressure; increase infusion by 2.5 mg/hour every 15 minutes to a maximum of 15 mg/hour; may increase infusion rate every 5 minutes if a more rapid blood pressure reduction is required; once desired blood pressure is achieved, decrease infusion rate to 3 mg/hour. Monitor and titrate to lowest dose necessary to maintain stable blood pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Substitution for oral nicardipine therapy (approximate equivalents):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral dose of 20 mg every 8 hours = 0.5 mg/hour I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral dose of 30 mg every 8 hours = 1.2 mg/hour I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral dose of 40 mg every 8 hours =  2.2 mg/hour I.V. infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Specific guidelines are not available; careful monitoring and dosage adjustment is warranted. Adult: Oral: Titrate dose carefully beginning with usual initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Specific guidelines are not available; use with caution in patients with severe hepatic impairment; careful monitoring and dosage adjustment is warranted. Adult: Oral: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Titrate dose carefully beginning with 20 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustained release: Has not been studied",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 20 mg, 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sustained release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardene&reg; SR: 30 mg, 45 mg, 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardene&reg; I.V.: 20 mg (200 mL); 40 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic sodium chloride solution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardene&reg; I.V.: 20 mg (200 mL); 40 mg (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 2.5 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardene&reg; I.V.: 2.5 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule, injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1027476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered without regard to meals; avoid concurrent administration with high-fat meals or grapefruit juice. Swallow sustained release capsule whole; do not crush, break, or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer by slow I.V. continuous infusion; I.V. product must be diluted prior to administration; may dilute with  D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     W with KCl 40 mEq, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS; manufacturer recommended concentration for infusion: 100 mcg/mL;",
"     <b>",
"      Note:",
"     </b>",
"     One pediatric study used infusions of 500 mcg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or other compatible solution (Flynn, 2001). Avoid extravasation.",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     100",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"     <b>",
"      or",
"     </b>",
"     500",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1027458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W with KCl 40 mEq, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with sodium bicarbonate 5%, LR",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Diltiazem, dobutamine, dopamine, epinephrine, fentanyl, gatifloxacin, hydromorphone, labetalol, linezolid, lorazepam, midazolam, milrinone, morphine, nitroglycerin, norepinephrine, ranitidine, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide, heparin, thiopental",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1027455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsules (immediate and sustained-release): Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); dispense in light-resistant container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Store at room temperature; protect from light (store ampuls in carton before use); avoid exposure to elevated temperatures; freezing does not affect stability; diluted solution (100 mcg/mL) is stable for 24 hours at room temperature",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compatible in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     W with KCl 40 mEq, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS for 24 hours when stored at controlled room temperature in glass or polyvinyl chloride containers;",
"     <b>",
"      not",
"     </b>",
"     compatible with sodium bicarbonate 5% or LR",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1027434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release product: Treatment of chronic stable angina; hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sustained release product: Treatment of hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Short-term treatment of hypertension when oral treatment is not possible",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F201224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NiCARdipine may be confused with niacinamide, NIFEdipine, niMODipine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cardene&reg; may be confused with Cardizem&reg;, Cardura&reg;, codeine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cardene [U.S., Great Britain, Netherlands] may be confused with Cardem brand name for celiprolol [Spain]; Cardin brand name for simvastatin [Poland]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F201221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain (I.V.), ECG abnormal, extrasystoles (I.V.), flushing, hemopericardium (I.V.), hyper-/hypotension (I.V.), increased angina (dose related), orthostasis, palpitation, peripheral edema (dose related), supraventricular tachycardia (I.V), syncope, tachycardia, vasodilation, ventricular extrasystoles (I.V.), ventricular tachycardia (I.V.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, hypoesthesia, intracranial hemorrhage, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (I.V.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (I.V.), dry mouth, dyspepsia, nausea, vomiting (I.V.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain/reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal ECG, allergic reaction, constipation, deep vein thrombophlebitis; ECG effects (AV block, inverted T wave, ST segment depression); gingival hyperplasia, hypophosphatemia, insomnia, malaise, nervousness, nocturia, parotitis, thrombocytopenia, tinnitus, tremor, ventricular extrasystoles",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1027439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nicardipine or any component; advanced aortic stenosis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2934428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution and carefully titrate the dose in patients with cardiac, renal, or hepatic dysfunction or reduced liver blood flow; decrease the starting dose for patients with severe hepatic dysfunction. Use I.V. formulation with caution in patients with pheochromocytoma (limited clinical experience) and portal hypertension (may cause increase hepatic venous pressure gradient). Peripheral infusion sites (for I.V. therapy) should be changed every 12 hours to minimize venous irritation. Abrupt withdrawal may cause rebound angina in patients with CAD. Use of immediate release product for treatment of hypertension may result in relatively large differences in peak and trough blood pressures (compared to sustained release product). Safety and efficacy have not been demonstrated in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1027440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic hypotension may occur; monitor blood pressure carefully; lowering of blood pressure should be done at a rate appropriate for the patient&rsquo;s condition; rapid drops in blood pressure may lead to arterial insufficiency; avoid systemic hypotension in patients following an acute cerebral infarct or hemorrhage.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Nicardipine may increase frequency, duration, or severity of angina with initiation of therapy or dosage increase (use with caution in patients with CAD). May cause negative inotropic effects in some patients (use with caution in patients with CHF or significant left ventricular dysfunction, especially when used in combination with beta-blockers).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F201209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (moderate), CYP2C9 (strong), CYP2D6 (moderate), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of NiCARdipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1027454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     A high-fat meal may decrease nicardipine peak concentrations and the extent of absorption; however, in the clinical trials that established safety and efficacy, the immediate and sustained release capsules were administered without regard to meals. Administration of sustained release capsule with a high-fat meal reduces fluctuations in serum concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Grapefruit juice may increase nicardipine serum concentrations (avoid concurrent use); avoid natural licorice (causes sodium and water retention and increases potassium loss)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Nicardipine has been used for the treatment of severe hypertension in pregnancy and pre-term labor. Nicardipine crosses the placenta; changes in fetal heart rate, neonatal hypotension and neonatal acidosis have been observed following maternal use (rare; based on limited data). Adverse effects reported in pregnant women are generally similar to those reported in non pregnant patients; however pulmonary edema has been observed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2934443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Blood pressure, heart rate, liver and renal function;",
"     <b>",
"      Note:",
"     </b>",
"     Monitor blood pressure carefully during initiation of therapy and with dosage adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release product: Measure blood pressure at peak effects (1-2 hours after the dose) especially during initiation of therapy, and just prior to the next dose (to ensure control of blood pressure throughout dosing interval).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sustained release product: Measure blood pressure 2-4 hours after the first dose or dosage increase and just prior to the next dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Monitor infusion site for extravasation; monitor blood pressure continuously during I.V. administration",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1027459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium ions from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization; produces a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2934410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Antihypertensive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate capsules: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustained release capsules (at steady state): Sustained from 2-6 hours postdose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. continuous infusion: 50% of the maximum effect is seen by 45 minutes; final effect of a continuously infused dose is seen by 50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release capsules: &lt;8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustained release capsules: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Single dose: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. continuous infusion: Upon discontinuation, a 50% decrease in effect is seen in ~30 minutes with gradual discontinuing antihypertensive effects for ~50 hours.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1027461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Absorption: Oral: ~100%, but large first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 8.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive, saturable, first-pass effect; dose-dependent (nonlinear) pharmacokinetics; extensive hepatic metabolism; major pathway is via cytochrome P450 isoenzyme CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Follows dose-dependent (nonlinear) pharmacokinetics; &ldquo;apparent&rdquo; or calculated half-life is dependant upon serum concentrations. Half-life over the first 8 hours after oral dosing is 2-4 hours; terminal half-life (oral): 8.6 hours. After I.V. infusion, serum concentrations decrease tri-exponentially; alpha half-life: 2.7 minutes; beta half-life: 44.8 minutes; terminal half-life: 14.4 hours (",
"     <b>",
"      Note:",
"     </b>",
"     Terminal half-life can only be seen after long-term infusions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release capsule: 30-120 minutes (mean: 1 hour)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustained release capsule: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 60% of an oral dose is excreted in the urine (&lt;1% as unchanged drug); 35% excreted in feces.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Decreased in patients with hepatic dysfunction; may be decreased in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1027482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/10/12453?source=see_link\">",
"      see \"Nicardipine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. May cause low blood pressure upon standing; rise slowly from prolonged sitting or lying position. Avoid alcohol and grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Do not discontinue abruptly; report any dizziness, shortness of breath, palpitations, chest pain, rapid heart beat, swelling of extremities, muscle weakness or pain, or nervousness. Some medicines may interact with nicardipine; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist; avoid the herbal medicine St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F2934667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Nicardipine has been used in children for controlled hypotension to limit intraoperative blood loss (Tobias, 2002).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The sustained release capsule contains a powder component (containing 25% of the dose) and a spherical granule component (containing 75% of the dose). The I.V. product is buffered to a pH of 3.5.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/ 12748199 /pubmed\" id=\" 12748199 \" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT and Pasko DA, \"Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2000, 15(3-4):302-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/11149130/pubmed\" id=\"11149130\" target=\"_blank\">",
"        11149130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT, Mottes TA, Brophy PD, et al, \"Intravenous Nicardipine for Treatment of Severe Hypertension in Children,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 139(1):38-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/11445792 /pubmed\" id=\"11445792 \" target=\"_blank\">",
"        11445792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gouyon JB, Geneste B, Semama DS, et al, \"Intravenous Nicardipine in Hypertensive Preterm Infants,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 1997, 76(2):F126-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/9135293/pubmed\" id=\"9135293\" target=\"_blank\">",
"        9135293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larsen A and Tobias J, \"Nicardipine for the Treatment of Hypertension Following Cardiac Transplantation in a 14-Year-Old Boy,\"",
"      <i>",
"       Clin Pediatr (Phila)",
"      </i>",
"      , 1994, 33(5):309-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/8050261/pubmed\" id=\"8050261\" target=\"_blank\">",
"        8050261",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McBride BF, White CM, Campbell M, et al, \"Nicardipine to Control Neonatal Hypertension During Extracorporeal Membrane Oxygen Support,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(5):667-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/12708943/pubmed\" id=\"12708943\" target=\"_blank\">",
"        12708943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Michael J, Groshong T, and Tobias JD, \"Nicardipine for Hypertensive Emergencies in Children With Renal Disease,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 1998, 12(1):40-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/9502566 /pubmed\" id=\"9502566 \" target=\"_blank\">",
"        9502566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Milou C, Debuche-Benouachkou V, Semama DS, et al, \"Intravenous Nicardipine as a First-Line Antihypertensive Drug in Neonates,\"",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2000, 26(7):956-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/10990112/pubmed\" id=\"10990112\" target=\"_blank\">",
"        10990112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nakagawa TA, Sartori SC, Morris A, et al, \"Intravenous Nicardipine for Treatment of Postcoarctectomy Hypertension in Children,\"",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 2004, 25(1):26-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/14534761/pubmed\" id=\"14534761\" target=\"_blank\">",
"        14534761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steele RM, Schuna AA, and Schreiber RT, &ldquo;Calcium Antagonist-Induced Gingival Hyperplasia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 120(8):663-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/8135450 /pubmed\" id=\"8135450 \" target=\"_blank\">",
"        8135450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobias JD, \"Nicardipine to Control Mean Arterial Pressure After Cardiothoracic Surgery in Infants and Children,\"",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 2001, 8(1):3-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/11304651/pubmed\" id=\"11304651\" target=\"_blank\">",
"        11304651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treluyer JM, Hubert P, Jouvet P, et al, \"Intravenous Nicardipine in Hypertensive Children,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 1993, 152(9):712-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/38/32361/abstract-text/8223797/pubmed\" id=\"8223797\" target=\"_blank\">",
"        8223797",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12925 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-0B2EC3AACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32361=[""].join("\n");
var outline_f31_38_32361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201178\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027433\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443902\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027471\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201152\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201138\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027476\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472950\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027458\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027455\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027434\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201224\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201221\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027439\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934428\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027440\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201209\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201147\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027454\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201149\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201162\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934443\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027459\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934410\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027461\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1027482\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934667\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12925\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12925|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=related_link\">",
"      Nicardipine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/10/12453?source=related_link\">",
"      Nicardipine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_38_32362="Prevention and treatment of diabetic retinopathy";
var content_f31_38_32362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of diabetic retinopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/38/32362/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32362/contributors\">",
"     Claire E Fraser, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32362/contributors\">",
"     Donald J D'Amico, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/38/32362/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32362/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32362/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/38/32362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/38/32362/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/38/32362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic retinopathy (DR) is one of the most important causes of visual loss worldwide, and is the principal cause of impaired vision in patients between 25 and 74 years of age. The prevalence of DR increases with duration of diabetes. Additional risk factors include the level of glycemic control, the type of diabetes (type 1 more than type 2), and the presence or absence of associated conditions such as hypertension, smoking, dyslipidemia, nephropathy, and pregnancy.",
"   </p>",
"   <p>",
"    Several preventive and therapeutic interventions have been evaluated in an attempt to minimize the morbidity associated with diabetic retinopathy. Treatment of diabetic retinopathy is directed both at prevention (primarily by good glycemic control) and at treatment of established disease.",
"   </p>",
"   <p>",
"    Strict glycemic control early in the course of diabetes and photocoagulation for established disease are of primary importance. Vitrectomy can also be used to preserve useful vision in advanced cases and certain circumstances. Intravitreal pharmacologic therapies are important new modalities for the treatment of diabetic retinopathy.",
"   </p>",
"   <p>",
"    Treatment of diabetic retinopathy will be reviewed here. The screening, pathogenesis, and clinical features of diabetic retinopathy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42501?source=see_link\">",
"     \"Screening for diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=see_link\">",
"     \"Classification and clinical features of diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=see_link\">",
"     \"Pathogenesis of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES TO REDUCE RISK AND PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of diabetic retinopathy (DR) increases with the duration of diabetes (",
"    <a class=\"graphic graphic_figure graphicRef70042 \" href=\"mobipreview.htm?24/45/25309\">",
"     figure 1",
"    </a>",
"    ). Additional risk factors include a lesser degree of glycemic control, the type of diabetes (type 1 more than 2), and the presence of associated conditions such as hypertension, smoking, nephropathy, dyslipidemia, and pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these factors are strongly predictive of the development and severity of retinopathy in populations, it is difficult to predict the development of retinopathy in a particular individual. As an example, many patients are under the impression that they will not develop retinopathy if they maintain good glycemic control. While lower A1C levels are associated with a decreased risk of retinopathy development and progression, good glycemic control does not guarantee that retinopathy will not develop or preclude regular screening for diabetic retinopathy (",
"    <a class=\"graphic graphic_table graphicRef61833 \" href=\"mobipreview.htm?17/18/17707\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42501?source=see_link\">",
"     \"Screening for diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review of trials for the treatment of diabetic retinopathy showed that strict glycemic and blood pressure control were beneficial for the prevention and progression of retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, the benefit of lipid lowering therapy to reduce the risk of retinopathy was less certain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Lipid lowering therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a subsequent study not included in the systematic review, the ACCORD Eye Study, the effect of intensive glycemic, blood pressure, and lipid control on progression of diabetic retinopathy was evaluated in a subset of 2856 adults participating in the ACCORD trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/5\">",
"     5",
"    </a>",
"    ]. Progression of diabetic retinopathy was defined by a three or more step progression on the Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale, or the development of proliferative retinopathy requiring photocoagulation or vitrectomy. At four years, progression of retinopathy occurred in 253 patients (8.9 percent). Among these patients, a three or more step progression on the ETDRS scale occurred in 69 percent, but only 12 percent of these patients required laser photocoagulation and 4 percent required vitrectomy. There was a reduction in the proportion of patients with progression of retinopathy in the intensive glycemic therapy group and the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    group, but not in the intensive blood pressure control group. No benefits of any intervention were seen for moderate loss of vision. Additional details are provided below and elsewhere. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Goal blood pressure'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Lipid lowering therapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H11243121#H11243121\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'ACCORD trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'ACCORD BP trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'ACCORD Lipid trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with diabetes, we recommend maintaining both glycemic (A1C &le;7 percent) and blood pressure control. Most patients with type 2 diabetes will require treatment with statins to control hyperlipidemia; however, we do not specifically suggest lipid lowering therapy for the treatment or prevention of retinopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good glycemic control reduces the incidence and progression of retinopathy in patients with type 1 and 2 diabetes. The efficacy of strict glycemic control is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H2#H2\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Hyperglycemia and Microvascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reviewed briefly, strict glycemic control, achieving a mean HbA1c of 7 percent versus 9 percent with conventional therapy, was associated with the following benefits over a mean follow-up of 6.5 years in the Diabetes Control and Complications Trial (DCCT) of patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is highly effective in primary prevention of retinopathy. In one DCCT analysis, new retinopathy was reduced by 76 percent during a mean of 6.5 years of intensive versus conventional metabolic control (incidence of 54 versus 12 percent in conventionally and intensively treated patients, respectively). The degree of protection is directly related to the degree of glycemic control; progressive retinopathy is uncommon in patients with hemoglobin A1C (A1C) values below 7 percent (",
"      <a class=\"graphic graphic_figure graphicRef82664 \" href=\"mobipreview.htm?42/55/43901\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      It is highly effective in slowing the rate of progression of retinopathy in patients with very mild to moderate nonproliferative retinopathy at baseline (54 percent reduction) (",
"      <a class=\"graphic graphic_figure graphicRef61305 \" href=\"mobipreview.htm?28/32/29197\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In other studies, glycemic control was of little or no benefit in patients with advanced retinopathy as shown from studies with two-year follow-up in which normoglycemia was attained with pancreas transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The long-term follow-up of the DCCT cohort in the Epidemiology of Diabetes Interventions and Complications (EDIC) Study showed that the beneficial effects of intensive therapy during DCCT persisted even though the A1C differences between the two treatment groups dissipated. This so called &ldquo;metabolic memory&rdquo; appears to persist for as long as 10 years after the end of the DCCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the long-term effectiveness of glycemic control, there is often transient worsening of the retinopathy during the first year of intensive glycemic management (",
"    <a class=\"graphic graphic_figure graphicRef61305 \" href=\"mobipreview.htm?28/32/29197\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=see_link&amp;anchor=H11#H11\">",
"     \"Classification and clinical features of diabetic retinopathy\", section on 'Transient worsening with intensive insulin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two issues related to the use of antihypertensive therapy in patients with diabetic retinopathy: &ldquo;What is the goal blood pressure?&rdquo; and &ldquo;Does angiotensin inhibition provide additional benefit as it does in diabetic nephropathy?&rdquo; (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;More rigorous control of hypertension slows the rate of progression of diabetic retinopathy and reduces the risk of vitreous hemorrhage. This was illustrated in the United Kingdom Prospective Diabetes Study (UKPDS) in which 1148 patients with type 2 diabetes were randomly assigned to a goal blood pressure",
"    <span class=\"nowrap\">",
"     &lt;150/85",
"    </span>",
"    mmHg or",
"    <span class=\"nowrap\">",
"     &lt;180/105",
"    </span>",
"    mmHg with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    as primary therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/9\">",
"     9",
"    </a>",
"    ]. The mean blood pressure at study entry was",
"    <span class=\"nowrap\">",
"     160/94",
"    </span>",
"    mmHg and the achieved mean blood pressures in the two groups were",
"    <span class=\"nowrap\">",
"     144/82",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     154/87",
"    </span>",
"    mmHg.",
"   </p>",
"   <p>",
"    At eight to nine years, patients in the lower blood pressure group had a 24 percent reduction in diabetes-related end points and a 34 and 47 percent reduction in significant deterioration in retinopathy and visual acuity, respectively. Diastolic blood pressure may be a better predictor of progression of retinopathy than systolic blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The attained blood pressures in UKPDS were higher than the currently recommended goal blood pressure in patients with diabetes. In subsequent trials, such as ADVANCE and ACCORD, attained blood pressures were lower (ie,",
"    <span class=\"nowrap\">",
"     &le;140/80",
"    </span>",
"    in both the active intervention and control groups), and these trials did not show an effect on retinopathy outcomes. As an example, in the ACCORD Eye Study, baseline median systolic blood pressure was 137 mmHg, with achieved systolic blood pressures of 117 and 133 mmHg in the intensive and standard therapy groups, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/5\">",
"     5",
"    </a>",
"    ]. There was no difference in progression of retinopathy between the two groups (10.4 versus 8.8, odds ratio 1.23, 95% CI 0.84-1.79), probably due to the relatively good blood pressure control in both groups. With the blood pressure levels achieved in the ACCORD Eye Study and in ADVANCE, longer-term follow-up may be necessary to show a protective effect of more aggressive blood pressure lowering. These trials are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Is angiotensin inhibition preferred?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of angiotensin inhibition on prevention of diabetic retinopathy, independent of the benefits of blood pressure control, is unclear. Comparative trials have not found angiotensin converting enzyme (ACE) inhibitors to be superior to a beta blocker or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/49/22295?source=see_link\">",
"     nisoldipine",
"    </a>",
"    in hypertensive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] or normotensive",
"    <span class=\"nowrap\">",
"     (&lt;140/90",
"    </span>",
"    mmHg) patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Placebo-controlled trials have provided some evidence of benefit, but it was not possible to separate the effects of angiotensin inhibition from those due to blood pressure lowering. In two trials with a secondary goal of studying retinopathy outcomes in normotensive (mean",
"    <span class=\"nowrap\">",
"     120/70",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     123/80",
"    </span>",
"    mmHg) patients with type 1 diabetes and minimal (predominantly NPDR) or no retinopathy, the following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the EUCLID trial, patients who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      rather than placebo had a significantly lower rate of retinopathy progression by one EDTRS steps or more (13 versus 23 percent) and of proliferative retinopathy (1.2 versus 6.6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/14\">",
"       14",
"      </a>",
"      ]. The mean systolic blood pressure was 3 mmHg lower in the lisinopril than the placebo group.",
"     </li>",
"     <li>",
"      In the Renin Angiotensin System Study (RASS), patients who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      rather than placebo had a significantly lower rate of retinopathy progression by two EDTRS steps or more (25 and 21 versus 38 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/15\">",
"       15",
"      </a>",
"      ]. The mean blood pressure was 2 to",
"      <span class=\"nowrap\">",
"       4/2",
"      </span>",
"      mmHg lower in the active treatment group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best data come from the Diabetic Retinopathy",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     Candesartan",
"    </a>",
"    Trials (DIRECT) Programme, which investigated the effects of candesartan on the development and progression of diabetic retinopathy in type 1 diabetes and on progression in type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/16\">",
"     16",
"    </a>",
"    ]. In this multicenter international trial, normoalbuminuric normotensive patients with type 1 diabetes with (1905 subjects) or without (1421 subjects) baseline nonproliferative retinopathy and 1905 normoalbuminuric normotensive or treated hypertensive subjects with type 2 diabetes and nonproliferative retinopathy were randomly assigned to candesartan (32 mg daily) or placebo.",
"   </p>",
"   <p>",
"    The following findings were noted in patients with type 1 diabetes (DIRECT-1) at a median follow-up of about 4.7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients without retinopathy at baseline, new retinopathy (change in two or more Early Treatment Diabetic Retinopathy Study [ETDRS] levels) was significantly less likely in patients assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      (25 versus 31 percent, HR 0.82, 95% CI 0.67-1.00). This effect was attenuated and no longer significant after adjustment for systolic blood pressure, which was 2.6 mmHg lower in the candesartan group (HR 0.92, 95% CI 0.75-1.13).",
"     </li>",
"     <li>",
"      Among patients who had retinopathy at baseline, there was no difference in the rate of progression of retinopathy (13 percent in each group, defined as three or more ETDRS levels) even though the blood pressure was",
"      <span class=\"nowrap\">",
"       3.6/2.5",
"      </span>",
"      mmHg lower in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following findings were noted in patients with type 2 diabetes (DIRECT-2) at a median follow-up of 4.7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among all patients, there was no difference in progression of retinopathy by three steps or more ETDRS levels (17 versus 19 percent for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      and placebo, respectively, HR 0.87, 95% CI 0.70-1.08) even though mean blood pressure was lower in the candesartan group (by",
"      <span class=\"nowrap\">",
"       4.3/2.5",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       2.9/1.3",
"      </span>",
"      mmHg in patients receiving and not receiving antihypertensive medication at baseline, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Regression of retinopathy occurred significantly more often in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"       candesartan",
"      </a>",
"      group (19 versus 14 percent, adjusted HR 1.33, 95% CI 1.06-1.67). In a subgroup analysis, the chance of regression was significant only in those with mild retinopathy at baseline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results from DIRECT-2 differ from the trials described above in that the decrease in blood pressure in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    group was not associated with a reduction in progression of retinopathy. This may be due, at least in part, to the more stringent definition of progression of retinopathy in DIRECT-2 (increase in three or more ETDRS levels compared with one or two or more in EUCLID and RASS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the difference in mean blood pressure between the intervention and control groups was smaller and blood pressure control at baseline was similar or better in DIRECT-2 than in other trials in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. The better blood pressure control in DIRECT-2 was associated with fewer retinopathy events, making it more difficult to show benefit from blood pressure reduction.",
"   </p>",
"   <p>",
"    In summary, the trials described above suggest that good blood pressure control is important for prevention and for slowing progression of diabetic retinopathy. There are insufficient data to recommend a specific antihypertensive agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lipid lowering therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of lipid lowering therapy for the prevention of diabetic retinopathy has not been well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In large randomized trials of cholesterol lowering therapy for the prevention of heart disease, the effect of therapy on retinopathy progression has been included as a tertiary endpoint. As an example, in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     Fenofibrate",
"    </a>",
"    Intervention and Event Lowering in Diabetes (FIELD) trial, 9795 patients ages 50 to 75 with type 2 diabetes were randomly assigned to receive micronized fenofibrate 200 mg daily or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    were less likely than controls to require laser treatment and to experience progression of retinopathy. However, the study was limited by incomplete reporting of the severity of retinopathy and indications for laser therapy. In addition, there was a nonsignificant increase in coronary and all-cause mortality. The details of the primary cardiac outcomes of the FIELD trial are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'FIELD trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few lipid intervention trials that have assessed the development or progression of retinopathy as a primary outcome. In one such trial, 50 patients with type 1 or 2 diabetes, hypercholesterolemia, and retinopathy (without clinically significant macular edema) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (20 mg daily) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/19\">",
"     19",
"    </a>",
"    ]. After six months, visual acuity and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography findings worsened in more patients in the placebo than simvastatin group (seven versus zero). These findings suggest that simvastatin may slow the progression of retinopathy.",
"   </p>",
"   <p>",
"    In the ACCORD Eye Study described above, there was a reduction in the proportion of patients with progression of retinopathy in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    group (6.5 versus 10.2 percent, OR 0.60, 95% CI 0.42-0.87) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/5\">",
"     5",
"    </a>",
"    ]. Fenofibrate decreased triglyceride levels compared with placebo (120 versus 147",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.4 versus 1.7",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    Further evaluation of fenofibrate for primary prevention or secondary intervention of diabetic retinopathy is warranted.",
"   </p>",
"   <p>",
"    Because lipid abnormalities are common in patients with diabetes mellitus, and especially in type 2 diabetes, many patients with type 2 diabetes will require hypolipidemic therapy (a statin) to decrease the risk of cardiovascular disease. The optimal therapy of dyslipidemia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H13#H13\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Multifactorial risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multifactorial risk reduction strategy has been examined in the Steno type 2 diabetes study, and results indicate that intensive treatment to concurrently address glycemic control, hypertension, hyperlipidemia, and nephropathy also reduces the progression of DR. The details of the protocol and overall results of this study are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Multifactorial risk factor reduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because ischemia contributes to the ocular complications of diabetes, the use of antiplatelet agents has been studied as a possible treatment strategy, as well as for safety issues. However, the largest randomized trial to date found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    had no beneficial effect on the development or progression of proliferative retinopathy, vitreous bleeding, or visual loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This trial, as well as a meta-analysis of other randomized clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/20\">",
"     20",
"    </a>",
"    ], also suggests that there are no ophthalmologic contraindications to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in diabetic patients, in whom aspirin is an important drug for cardiovascular risk reduction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/44/7881?source=see_link&amp;anchor=H4#H4\">",
"     \"Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage\", section on 'Antiplatelet agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other preventive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents that may prevent or slow the progression of retinopathy are under investigation. As an example, carbonic anhydrase plays a role in retinal vascular permeability in DR and, therefore, carbonic anhydrase inhibitors may slow the development of retinopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis of diabetic retinopathy\", section on 'Carbonic anhydrase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, calcium dobesilate, a drug that decreases capillary permeability, platelet aggregation, and blood viscosity, and that is used in some countries to treat chronic venous insufficiency and DR, was not shown to prevent the occurrence of clinically significant macular edema in subjects with non-proliferative diabetic retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT OF NPDR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual loss in nonproliferative diabetic retinopathy (NPDR) is primarily through the development of macular edema (ME). Thus, mild and moderate NPDR are generally not treated, unless accompanied by clinically significant macular edema (CSME) (",
"    <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62206 \" href=\"mobipreview.htm?40/7/41085\">",
"     table 3",
"    </a>",
"    ). Focal photocoagulation is the treatment of choice when CSME is present. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Treatment of diabetic macular edema'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In some type 2 diabetic patients with severe or very severe NPDR and a higher risk of rapid progression to proliferative diabetic retinopathy (PDR), panretinal laser photocoagulation (PRP) reduces the risk of progression to high risk PDR and should be considered in this subgroup of patients (",
"    <a class=\"graphic graphic_table graphicRef62206 \" href=\"mobipreview.htm?40/7/41085\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Panretinal photocoagulation'",
"    </a>",
"    below.) The risk of rapid progression is often determined by funduscopic or angiographic findings. However, clinical factors, which may influence the decision to perform PRP, include a history of proliferative disease or poor vision in the fellow eye, poorly controlled diabetes, and high risk for being lost to follow-up.",
"   </p>",
"   <p>",
"    Pharmacologic therapy for NPDR without ME is in the early investigational stages. Protein kinase C inhibitors (eg, ruboxistaurin) and aldose reductase inhibitors have been evaluated in clinical trials with no evidence of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39207?source=see_link&amp;anchor=H6#H6\">",
"     \"Protein kinase C and the vascular complications of diabetes mellitus\", section on 'Inhibitors of PKC'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/13000?source=see_link&amp;anchor=H6#H6\">",
"     \"Aldose reductase inhibitors in the prevention of diabetic complications\", section on 'Retinopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT OF PDR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment of proliferative diabetic retinopathy (PDR) include preservation of remaining vision, reduction in the rate of progression, and repair of lesions when possible. A number of surgical methods have proven useful to achieve these goals (",
"    <a class=\"graphic graphic_table graphicRef62206 \" href=\"mobipreview.htm?40/7/41085\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Panretinal photocoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panretinal photocoagulation (PRP) is the primary treatment for high risk and severe PDR (",
"    <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"     table 2",
"    </a>",
"    ). Laser photocoagulation makes use of wavelengths that pass through the ocular media but are absorbed by pigment in the retinal pigment epithelium which underlies the transparent retina. Typical treatment includes 600 to 1600 burns, 500 micrometers in size, placed on the retina in a grid pattern that includes confluent coverage of neovascularization not involving the optic disc (",
"    <a class=\"graphic graphic_picture graphicRef77583 \" href=\"mobipreview.htm?32/26/33185\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The efficacy of PRP has been demonstrated in several randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/26-28\">",
"     26-28",
"    </a>",
"    ] and summarized in a 2007 systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/3\">",
"     3",
"    </a>",
"    ]. In the Diabetic Retinopathy Study, where 1758 diabetic patients with advanced retinopathy were assigned to panretinal photocoagulation in one eye (with the other eye being the control), the cumulative risk of developing severe visual loss at six years was reduced by more than 50 percent in the treated eyes (",
"    <a class=\"graphic graphic_figure graphicRef72517 \" href=\"mobipreview.htm?23/34/24109\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/26\">",
"     26",
"    </a>",
"    ]. A similar magnitude of benefit was noted in the systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, regression of neovascularization occurs in 30 to 55 percent of eyes after PRP and may correlate with visual prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/26,29\">",
"     26,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regression of proliferative retinopathy following PRP is affected by the level of glycemic control during the pretreatment, treatment, and posttreatment periods. In an observational study of 76 type 2 diabetic patients undergoing photocoagulation (115 eyes treated), 57 percent had a successful response at 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/30\">",
"     30",
"    </a>",
"    ]. The probability of having a satisfactory response to PRP was greater in those with lower A1C values (odds ratio [OR] of response to PRP among subjects with A1C &gt;8.0 compared with A1C &lt;8.0 0.28, 95% CI 0.13-0.62).",
"   </p>",
"   <p>",
"    Indications for PRP treatment include high risk proliferative characteristics, rubeosis with or without neovascular glaucoma, moderate to severe neovascularization not involving the optic disc (especially in type 1 diabetic patients), and widespread retinal ischemia and capillary nonperfusion. PRP may also be considered if PDR is developing during a pregnancy or if preproliferative retinopathy is developing in the second eye of a type 1 diabetic with severe PDR in the other eye. Treatment considerations include individual response of the patient to previous laser treatment, any complications of the procedure (such as a decrease in visual fields), and other possibilities for additional therapy.",
"   </p>",
"   <p>",
"    We recommend PRP for individuals with high risk and severe PDR. PRP should be considered for some patients with early PDR or with severe or very severe NPDR, as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of PRP can include pain during treatment, transient increases in intraocular pressure, corneal abrasions, mydriasis due to damage of nerves in the uveal tract, macular edema and visual acuity loss, visual field loss, loss of dark adaptation, choroidal detachment or hemorrhage, exudative retinal detachment, subretinal neovascularization, vitreous hemorrhage from regression of neovascular tissue, lens opacities, and vascular occlusions.",
"   </p>",
"   <p>",
"    Pain during laser treatment is highly variable and depends in part upon the duration of the laser burns, pigmentation of the fundus, previous laser treatment, and patient anxiety. Similarly, the degree of visual field loss correlates with the percentage of retina ablated, the number of laser burns, the location and intensity of laser burns, and the patient's visual fields prior to laser treatment. Some impairment in dark adaptation is seen in approximately 75 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vitrectomy for PDR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure of laser therapy (PRP) to halt new vessel proliferation can result in severe visual impairment due to extensive vitreous hemorrhage. In addition to bleeding from fragile new vessels, vitreous hemorrhage can result from contraction of the vitreous or fibrovascular proliferation that leads to avulsion of a retinal vessel (",
"    <a class=\"graphic graphic_picture graphicRef74536 \" href=\"mobipreview.htm?27/51/28479\">",
"     picture 2",
"    </a>",
"    ). Blood behind the detached posterior vitreous face remains red and is absorbed over weeks to months. In contrast, blood in the formed vitreous can turn white over time and is absorbed more slowly. Removal of the opaque vitreous humor followed by photocoagulation to the retina can restore vision to the level that the retinal integrity permits.",
"   </p>",
"   <p>",
"    Tractional retinal detachments can also occur as a result of vitreal contraction and fibrovascular proliferation (",
"    <a class=\"graphic graphic_picture graphicRef71858 \" href=\"mobipreview.htm?39/54/40800\">",
"     picture 3",
"    </a>",
"    ). Retinal traction can decrease vision under the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When it results in a detachment involving the fovea",
"     </li>",
"     <li>",
"      When there is distortion or horizontal displacement of the macula (tangential traction)",
"     </li>",
"     <li>",
"      When fibrovascular proliferation obscures the fovea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proliferative retinopathy that progresses to vitreous hemorrhage or traction retinal detachment and vision loss can benefit from vitrectomy. In these cases, the major goals of vitrectomy are to remove media opacities (such as vitreous hemorrhage or cataract), to relieve vitreous traction, and to provide adequate retinal ablation by means of effective endophotocoagulation. Postoperative complications can include corneal defects, cataract formation, hemorrhage, retinal detachment, endophthalmitis, iris and angle neovascularization, and anterior hyaloidal fibrovascular proliferation.",
"   </p>",
"   <p>",
"    Observational studies have shown that 66 to 78 percent of patients with vitreous hemorrhage alone will have improved vision six months post-vitrectomy, as will 57 to 75 percent of patients with traction retinal detachment involving the fovea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/32-38\">",
"     32-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of vitrectomy is important. The Diabetic Retinopathy Vitrectomy Study trials have shown a benefit of early vitrectomy in some patients with advanced PDR, as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of early vitrectomy versus conventional management in 370 eyes with advanced retinal changes and visual acuity of",
"      <span class=\"nowrap\">",
"       10/200",
"      </span>",
"      or better, a greater proportion of eyes in the early vitrectomy group (44 versus 28 percent) had a visual acuity of",
"      <span class=\"nowrap\">",
"       10/20",
"      </span>",
"      or better after four years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/39\">",
"       39",
"      </a>",
"      ]. Early vitrectomy was most beneficial in the subgroup of patients with the most severe neovascularization.",
"     </li>",
"     <li>",
"      In another trial of 616 eyes with recent severe vitreous hemorrhage and visual acuity of",
"      <span class=\"nowrap\">",
"       &le;5/200",
"      </span>",
"      randomly assigned to early or deferred (for one year) vitrectomy, the proportion of eyes with visual acuity of",
"      <span class=\"nowrap\">",
"       10/20",
"      </span>",
"      or better was higher in the early vitrectomy group (25 versus 15 percent) over the four-year follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. Patients with type 1 diabetes and severe proliferative retinopathy had the most benefit from early vitrectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the indications for vitrectomy include vitreous hemorrhage that is nonclearing or prevents photocoagulation, traction retinal detachment involving the fovea, tangential traction of the macula resulting in visual loss, combined traction-rhegmatogenous retinal detachment, rubeosis precluding PRP, visual loss due to an epiretinal membrane or an opacified posterior vitreous face, and progressive neovascularization that is unresponsive to photocoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/40\">",
"     40",
"    </a>",
"    ]. Although the Diabetic Retinopathy Vitrectomy Study trials have some limitations, including the absence of endolaser use for surgical patients and the nonstandard application of PRP in the conventional subgroup, they showed that early vitrectomy may benefit those with the most advanced PDR and severe neovascularization. Thus, close monitoring of patients with advanced retinopathy by an ophthalmologist is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Medical vitrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enzymes such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/33/42512?source=see_link\">",
"     hyaluronidase",
"    </a>",
"    (Vitrase), chondroitinase, and plasmin may aid treatment of proliferative retinopathy. Intravitreal hyaluronidase has shown promise in clearing vitreous hemorrhage. Intravitreal plasmin has been used to cleave the vitreoretinal junction and allow less traumatic removal of the posterior hyaloid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. These enzymes have the potential to affect a pharmacologic vitrectomy and thereby reduce the need for surgery. Currently, these treatments are investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy for the treatment of PDR is investigational but is increasingly being used by some retinal specialists in particular circumstances or as an adjunct to conventional treatments (ie, vitrectomy or panretinal photocoagulation).",
"   </p>",
"   <p>",
"    More advanced retinal disease, including proliferative vascular changes and neovascularization in the setting of retinal ischemia, may be mediated by the action of vascular endothelial growth factor (VEGF). VEGF increases retinal vascular permeability and its effects are mediated, in part, by protein kinase C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/44\">",
"     44",
"    </a>",
"    ]. Therefore, inhibition of VEGF or protein kinase C may improve vascular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39207?source=see_link&amp;anchor=H6#H6\">",
"     \"Protein kinase C and the vascular complications of diabetes mellitus\", section on 'Inhibitors of PKC'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of diabetic retinopathy\", section on 'Growth factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     VEGF inhibitors for PDR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most promising pharmacologic treatments for proliferative retinopathy are antiangiogenic VEGF inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/54/42851?source=see_link\">",
"     pegaptanib",
"    </a>",
"    . Bevacizumab and ranibizumab are humanized antibodies that recognize all forms of the VEGF protein, whereas pegaptanib is an RNA aptamer (oligonucleotide ligand) that specifically binds and inhibits VEGF-165, the isoform primarily responsible for neovascularization and vascular permeability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/45\">",
"     45",
"    </a>",
"    ]. Ranibizumab and pegaptanib are currently used in the treatment of age-related macular degeneration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26074?source=see_link&amp;anchor=H7#H7\">",
"     \"Age-related macular degeneration: Treatment and prevention\", section on 'VEGF inhibitors and inhibitor-like drugs'",
"    </a>",
"    .) Bevacizumab is used in the treatment of colon and non-small cell lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H44#H44\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Agents targeting VEGF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779160#H525779160\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Chemotherapy plus bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are increasing numbers of case reports, prospective case series, and randomized trials documenting regression of diabetes-related neovascularization after single or repeated intravitreal injection of VEGF inhibitors, both with and without subsequent standard treatments such as photocoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/46-57\">",
"     46-57",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of a single intravitreal injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (1.25 mg) versus sham treatment in 80 eyes with PDR at their first standard PRP treatment session, a greater proportion of bevacizumab-treated eyes showed complete regression at six weeks (88 versus 25 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/58\">",
"       58",
"      </a>",
"      ]. However, PDR recurred in a substantial proportion of individuals treated with bevacizumab and by 16 weeks there was no difference in the rate of complete regression (25 percent).",
"     </li>",
"     <li>",
"      In an exploratory trial of intravitreal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/54/42851?source=see_link\">",
"       pegaptanib",
"      </a>",
"      (administered every six weeks for 30 weeks) versus PRP in 20 patients, the proportion of patients with complete regression of retinal neovascularization at 36 weeks was higher in the pegaptanib group (100 versus 25 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    has also been used in conjunction with vitrectomy to reduce postoperative complications such as recurrent hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/60\">",
"     60",
"    </a>",
"    ]. In two systematic reviews of randomized trials examining vitrectomy with or without pretreatment with bevacizumab, administration of bevacizumab (1.25 to 2.5 mg three to seven days prior to surgery) reduced early (&le;three weeks) postoperative recurrent vitreous cavity hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Whether pretreatment with bevacizumab significantly improves visual acuity compared with vitrectomy alone is uncertain. The majority of trials included in the systematic reviews were limited by significant methodological issues.",
"   </p>",
"   <p>",
"    Thus, VEGF inhibitors have been shown to shrink neovascularizations of the optic disc, retina, and iris, and decrease",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    leakage. When used as an adjunct, they have the potential to both bolster standard treatments, and reduce the need for additional photocoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/63\">",
"     63",
"    </a>",
"    ]. However, long-term efficacy and safety in patients with diabetes have not been established. Randomized trials of VEGF inhibitors, including alternative dosing schedules of multiple",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repeated intravitreal injections, for the treatment of PDR are required. In the interim, we do not recommend intravitreal VEGF inhibitors as routine initial therapy for PDR. VEGF inhibitors may be useful as adjunct therapy to PRP",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitrectomy for selected cases of PDR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Intravitreal glucocorticoids for PDR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravitreal glucocorticoids, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide, have also reduced neovascularization. However, unlike intravitreal injections of anti-VEGF molecules, intravitreal triamcinolone is associated with high rates of increased intraocular pressure, cataract formation, and endophthalmitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/64-67\">",
"     64-67",
"    </a>",
"    ] and, therefore, it is not used routinely for the treatment of PDR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing clinical trials of other pharmaceutical treatments for proliferative diabetic retinopathy can be found through the",
"    <a class=\"external\" href=\"file://drcrnet.jaeb.org/ViewPage.aspx?PageName=Home\">",
"     Diabetic Retinopathy Clinical Research Network",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT OF DIABETIC MACULAR EDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic treatment of macular edema (ME) that is not clinically significant is not recommended. However, treatment of clinically significant macular edema (",
"    <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"     table 2",
"    </a>",
"    ) is a rapidly evolving area, with laser treatment (focal photocoagulation) or intravitreal anti-VEGF pharmacotherapy currently the initial therapy of choice, with a complementary role for vitreous surgery. Furthermore, there is hope that refined pharmacologic therapies may provide for levels of visual acuity improvement not previously obtained with older therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Focal laser photocoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal photocoagulation is an established treatment for clinically significant macular edema (CSME) (",
"    <a class=\"graphic graphic_table graphicRef62206 \" href=\"mobipreview.htm?40/7/41085\">",
"     table 3",
"    </a>",
"    ). Focal laser photocoagulation can be performed directly on microaneurysms and on the microvascular lesions in the center of the rings of hard exudates, at least 500 microns from the fovea, or may be performed in the area of retinal edema without treating specific retinal vascular lesions. The mechanism of edema reduction after laser treatment is unknown, but many studies with minor technique variations suggest that it is most probably dependent on creating a grid pattern of light burns of the retinal pigment epithelium, which underlies the retina (",
"    <a class=\"graphic graphic_figure graphicRef51401 \" href=\"mobipreview.htm?15/1/15379\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The treatment is painless and takes less than 10 minutes to perform under topical anesthesia. Reduction of edema occurs over several weeks to several months, and although the treatment is highly efficacious compared with the expected progression of untreated CSME, the great majority of patients will achieve stabilization and, with longer follow-up, a modest improvement in acuity after therapy.",
"   </p>",
"   <p>",
"    The efficacy of focal photocoagulation for CSME was established in a large, randomized, prospective trial, the Early Treatment of Diabetic Retinopathy Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/68\">",
"     68",
"    </a>",
"    ]. For patients with CSME and mild to moderate NPDR, the most effective treatment strategy was immediate focal treatment with delay of panretinal photocoagulation until the development of more severe retinopathy. The risk of moderate visual loss decreased by 50 percent compared with eyes with deferral of treatment (",
"    <a class=\"graphic graphic_figure graphicRef81753 \" href=\"mobipreview.htm?17/24/17805\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Laser treatment may be repeated. The re-treatment decision is based on the persistence of retinal thickening and of leakage recorded by optical coherence tomography (OCT) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef88023 \" href=\"mobipreview.htm?29/33/30224\">",
"     image 1",
"    </a>",
"    ) and perhaps",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of focal laser photocoagulation for CSME include laser scars that tend to increase with time, para-central scotomas, accidental foveal photocoagulation (that may decrease visual acuity), \"creep\" of juxtafoveal laser scar into the fovea, choroidal neovascularization, and subfoveal fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While focal photocoagulation is the mainstay of treatment for diabetic CSME, rapid evolution in drug therapies is changing management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     VEGF inhibitors for ME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to their potential use in PDR, VEGF inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/54/42851?source=see_link\">",
"     pegaptanib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    ) have also been widely studied as a treatment for diabetic macular edema, and this therapy represents a major treatment advance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/69-79\">",
"     69-79",
"    </a>",
"    ]. In 2012, the US Food and Drug Administration approved a 0.3 mg intravitreal dose of ranibizumab for treatment of diabetic macular edema (ME). Consequently, for many patients and clinicians, intravitreal pharmacotherapy with ranibizumab will be the initial treatment of choice, but the precise interrelation between this treatment and other modalities is not yet conclusively defined.",
"   </p>",
"   <p>",
"    The efficacy of VEGF inhibitors for the treatment of diabetic macular edema is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of four trials comparing intravitreal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      with or without focal laser photocoagulation to controls, ranibizumab improved visual activity (two trials, mean difference 7.5 letters, 95% CI 3.43-11.58) and central macular thickness (two trials, mean difference -94.42 micrometers, 95% CI -174.22 to -14.62) at 12 months compared with no drug therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/80\">",
"       80",
"      </a>",
"      ]. Compared to laser alone, treatment with ranibizumab combined with laser also improved visual acuity (two trials, mean difference 5.83 letters, 95% CI 4.07-7.59) and central macular thickness (two trials, mean difference -46.82, 95% CI -83.98 to -9.65) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/80\">",
"       80",
"      </a>",
"      ]. There was no significant difference between ranibizumab alone or when combined with laser. In one study with longer-term follow-up, the combined group required the fewest number of ranibizumab injections during the 18-month follow-up period (2.9 compared with 5.3 and 4.4 in the ranibizumab-only and laser-only groups, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another meta-analysis of trials comparing a VEGF inhibitor (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/54/42851?source=see_link\">",
"       pegaptanib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"       ranibizumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"       aflibercept",
"      </a>",
"      ) with another treatment, sham treatment, or no treatment in patients with diabetic macular edema, VEGF inhibitors both increased the chances of gaining three or more lines of vision and decreased the risk of losing three or more lines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/81\">",
"       81",
"      </a>",
"      ]. Specifically, compared with grid laser photocoagulation (five trials), VEGF inhibitors (bevacizumab, ranibizumab, aflibercept) increased the chance of gaining three or more lines of vision (RR 3.20, 95% CI 2.07-4.95) and decreased the risk of losing three or more lines (RR 0.13, 95% CI 0.05-0.34). Compared to laser alone, combination ranibizumab plus photocoagulation approximately doubled the chances of gaining three or more lines of vision (RR 2.11, 95% CI 1.67-2.67) and decreased the chance of losing three or more lines (RR 0.29, 95% CI 0.15-0.55) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, combination therapy may provide immediate short-term benefit that is maintained in the longer-term with the least frequent intravitreal injections. Most data were obtained at one year, and additional longer-term studies are required to determine the optimal regimen for individual patients with varying degrees of DME.",
"   </p>",
"   <p>",
"    Potential adverse effects of VEGF inhibitors include transient increases in intraocular pressure. In one early study, endophthalmitis occurred as a complication of treatment in 0.8 percent of patients receiving the study drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/70\">",
"     70",
"    </a>",
"    ]. Subsequent larger studies show an approximate rate of 0.1 percent for endophthalmitis in patients receiving intravitreal injections of VEGF inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Although not demonstrated in clinical trials, observational data from patients treated with VEGF inhibitors for age-related macular degeneration suggest a higher risk of stroke in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    . Meta-analyses of trials comparing VEGF inhibitors with either sham or photocoagulation for diabetic macular edema (nine trials) did not show a significant difference for arterial thromboembolic events (RR 0.85, 95% CI 0.56-1.28) or overall mortality (33 events in 1262 patients versus 20 events in 897 patients, RR 0.95, 95% CI 0.52-1.74) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/81\">",
"     81",
"    </a>",
"    ]. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26074?source=see_link&amp;anchor=H7#H7\">",
"     \"Age-related macular degeneration: Treatment and prevention\", section on 'VEGF inhibitors and inhibitor-like drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3693387\">",
"    <span class=\"h3\">",
"     Intravitreal glucocorticoids for ME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    injection (IVTA) is an option for ME of any cause. Injection of 4 mg of triamcinolone acetonide produces a rapid reduction in macular thickness, often within days, and with a several line gain in visual acuity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/84-89\">",
"     84-89",
"    </a>",
"    ]. However, the treatment response in diabetic ME is transient. As a result, repeated injections are necessary, but these responses are also transient and adverse effects may be seen.",
"   </p>",
"   <p>",
"    These outcomes were illustrated by the results of a two-year trial of IVTA versus focal photocoagulation in which the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean visual acuity was significantly better in the photocoagulation group at two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/89\">",
"       89",
"      </a>",
"      ] and in the subset of patients who completed three years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At least 40 percent of patients treated with IVTA developed glaucoma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      significant cataracts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravitreal and retinal implants have been designed to deliver glucocorticoids over an extended time frame. The use of these implants is associated with even higher rates of cataract formation and glaucoma than IVTA injection.",
"   </p>",
"   <p>",
"    In the aggregate, the above findings have diminished the enthusiasm for IVTA as monotherapy for chronic ME. IVTA in combination with photocoagulation has been associated with a higher rate of sustained visual improvement than IVTA alone in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/91,92\">",
"     91,92",
"    </a>",
"    ] but not in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Larger clinical trials are required to clarify whether there is a role for IVTA with photocoagulation for the management of diabetic macular edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     VEGF inhibitors versus IVTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In randomized trials of a single intravitreal injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    (4 mg) versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (1.25 or 1.5 mg) in patients with refractory diabetic ME, there was a greater reduction in macular thickness and better visual acuity",
"    <span class=\"nowrap\">",
"     (20/100",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     20/160)",
"    </span>",
"    at 12 weeks with IVTA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. However, the improvements were transient in both treatment groups. In one trial, macular thickness and visual acuity returned to baseline within 12 weeks after injection of bevacizumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/96\">",
"     96",
"    </a>",
"    ]. The beneficial effects of IVTA lasted longer but were approaching baseline by 24 weeks. In addition, IVTA increased intraocular pressure more than bevacizumab.",
"   </p>",
"   <p>",
"    One large trial (691 participants, 854 eyes) evaluated intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    (0.5 mg) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetate (4 mg) combined with",
"    <span class=\"nowrap\">",
"     focal/grid",
"    </span>",
"    laser versus laser alone for the treatment of diabetic macular edema involving the fovea. After one year, the improvement in visual acuity was significantly greater in the ranibizumab plus laser group compared with laser alone (+nine versus +three letters). The difference between triamcinolone plus laser versus laser alone was not significant (+four versus +three letters) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional studies are required to determine the relative efficacy of IVTA and VEGF inhibitors, at single and repeated doses and in combination with",
"    <span class=\"nowrap\">",
"     focal/grid",
"    </span>",
"    laser, and their respective roles in the treatment of CSME.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical trial evaluating the role of ruboxistaurin in the treatment of diabetic ME did not show a reduction in the composite endpoint of ME progression or application of focal photocoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/98\">",
"     98",
"    </a>",
"    ]. Ruboxistaurin for the treatment of diabetic nephropathy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39207?source=see_link&amp;anchor=H6#H6\">",
"     \"Protein kinase C and the vascular complications of diabetes mellitus\", section on 'Inhibitors of PKC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6681989\">",
"    <span class=\"h2\">",
"     Vitrectomy for CSME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitrectomy may be beneficial in selective cases of CSME. However, the results of vitrectomy are somewhat variable, ranging from no benefit to visual acuity gains of several lines or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/99-103\">",
"     99-103",
"    </a>",
"    ]. Some authors advocate simple removal of the vitreous gel, others recommend additional removal of the thick posterior hyaloid, and still others perform both of these and also remove the internal limiting membrane (\"ILM peeling\") of the retina itself. A systematic review of trials assessing a combination of these techniques versus observation or focal photocoagulation reported that vitrectomy may be beneficial in some patients with CSME, particularly in those with evidence of vitreomacular traction, although the evidence was weak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reasonable expectation is to achieve a definite reduction in macular thickness one or more months after surgery, with a modest improvement of two or three lines of visual acuity. For these reasons, vitrectomy has generally been reserved for patients who have not had sufficient response to intravitreal pharmacotherapy and one or perhaps two or more laser treatments.",
"   </p>",
"   <p>",
"    Postoperative complications are similar to those described for vitrectomy for PDR. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Vitrectomy for PDR'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression of retinopathy is seen in 16 to 85 percent of diabetic women who become pregnant, although the long-term risk of progression does not differ with pregnancy. The Diabetes in Early Pregnancy study found that an increased risk of progression is associated with the severity of previously existing retinopathy and with poor glycemic control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/38/32362/abstract/104\">",
"     104",
"    </a>",
"    ]. Women who develop gestational diabetes are not at increased risk for the development of diabetic retinopathy. Women with diabetes who are planning pregnancy should have a comprehensive ophthalmic examination and receive counseling on the risk of development",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression of diabetic retinopathy. Diabetic women who become pregnant should be examined in the first trimester and closely followed until one year postpartum (",
"    <a class=\"graphic graphic_table graphicRef61833 \" href=\"mobipreview.htm?17/18/17707\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Treatment recommendations for pregnant women are the same as for other patients. Both laser therapy and vitreous surgery can be performed safely during pregnancy, if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/34/11810?source=see_link\">",
"       \"Patient information: Diabetic retinopathy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/21/44369?source=see_link\">",
"       \"Patient information: Detached retina (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic retinopathy is an increasingly important cause of visual loss. With proper screening, good control of glucose and blood pressure, and early intervention with both surgical and pharmacologic therapies, severe visual loss can be avoided in many patients. For the ophthalmologist, a management strategy must be tailored for each patient to maximize vision preservation and minimize side effects, based upon each patient's unique manifestations and progression of diabetic retinopathy. However, what follows are broad guidelines for the prevention and treatment of diabetic retinopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Lifestyle measures",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with diabetes, we recommend maintaining good glycemic control (A1C &le;7 percent) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Improved glycemic control reduces the risk and progression of retinopathy with no threshold effect. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link\">",
"       \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H2#H2\">",
"       \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Hyperglycemia and Microvascular disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We are aware that this goal is not appropriate for all patients, especially the elderly and those with comorbid conditions or limited life expectancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link&amp;anchor=H22#H22\">",
"       \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Summary and Recommendations'",
"      </a>",
"      .) In addition, the goal is not practical for all patients due to patient preferences regarding combination therapy, particularly insulin therapy.",
"     </li>",
"     <li>",
"      Maintaining good blood pressure is important for reducing the development and progression of DR. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antihypertensive therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The benefit of lipid lowering therapy for the prevention of diabetic retinopathy has not been well established. However, lipid abnormalities are common in patients with diabetes mellitus, and treatment with a statin is often recommended to decrease the risk of cardiovascular disease. The optimal therapy of dyslipidemia is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Treatment in diabetes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H13#H13\">",
"       \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Nonproliferative DR",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with",
"      <span class=\"nowrap\">",
"       severe/very",
"      </span>",
"      severe NPDR (",
"      <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"       table 2",
"      </a>",
"      ) who are at risk for rapid progression, we suggest panretinal photocoagulation (PRP) rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment of NPDR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with mild and moderate NPDR are generally not treated, unless accompanied by CSME. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment of diabetic macular edema'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Proliferative DR",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with high-risk and severe PDR (",
"      <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"       table 2",
"      </a>",
"      ), we recommend panretinal photocoagulation rather than medical therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). PRP may also be considered for some patients with early PDR, including individuals at risk for rapid progression (",
"      <a class=\"graphic graphic_table graphicRef62206 \" href=\"mobipreview.htm?40/7/41085\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Panretinal photocoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with type 1 diabetes and severe PDR (with vitreous hemorrhage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      traction involving the macula), we recommend early rather than delayed vitrectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Vitrectomy can also be considered in type 1 and type 2 patients with severe PDR unresponsive to PRP and as an adjunct to remove media opacity and permit adequate retinal laser ablation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Vitrectomy for PDR'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravitreal VEGF inhibitors may be useful as adjunct therapy to PRP",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitrectomy for selected cases of PDR. However, there are insufficient data to recommend their routine use. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'VEGF inhibitors for PDR'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Diabetic macular edema",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with clinically significant macular edema (ME) (",
"      <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"       table 2",
"      </a>",
"      ), we suggest intravitreal anti-VEGF therapy, either alone or with ancillary focal laser photocoagulation, as initial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Treatment can also be considered in patients with severe or very severe NPDR and ME and in those with PDR and ME (",
"      <a class=\"graphic graphic_table graphicRef62206 \" href=\"mobipreview.htm?40/7/41085\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'VEGF inhibitors for ME'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Focal laser photocoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with clinically significant macular edema (CSME) refractory to intravitreal anti-VEGF pharmacotherapy and photocoagulation and with evidence of vitreomacular traction, we suggest vitrectomy rather than continued medical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6681989\">",
"       'Vitrectomy for CSME'",
"      </a>",
"      above.) In the absence of vitreomacular traction, some experts will still consider vitrectomy as a therapy of last resort.",
"     </li>",
"     <li>",
"      Intravitreal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      may have some benefit in patients with refractory ME. However, these benefits are counterbalanced by an often transient response and an increased risk of side effects, including glaucoma and cataract. (See",
"      <a class=\"local\" href=\"#H3693387\">",
"       'Intravitreal glucocorticoids for ME'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/1\">",
"      Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998; 39:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/2\">",
"      Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010; 304:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/3\">",
"      Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 2007; 298:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/4\">",
"      Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/5\">",
"      ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/6\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/7\">",
"      Ramsay RC, Goetz FC, Sutherland DE, et al. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med 1988; 318:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/8\">",
"      Wang Q, Klein R, Moss SE, et al. The influence of combined kidney-pancreas transplantation on the progression of diabetic retinopathy. A case series. Ophthalmology 1994; 101:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/9\">",
"      Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/10\">",
"      Cohen RA, Hennekens CH, Christen WG, et al. Determinants of retinopathy progression in type 1 diabetes mellitus. Am J Med 1999; 107:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/11\">",
"      Matthews, DR, Stratton, IM, Aldington, SJ, et al. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004; 122:1631-40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/12\">",
"      Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 Suppl 2:B54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/13\">",
"      Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/14\">",
"      Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/15\">",
"      Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/16\">",
"      Sj&oslash;lie AK, Porta M, Parving HH, et al. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst 2005; 6:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/17\">",
"      Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/18\">",
"      Sj&oslash;lie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/19\">",
"      Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/20\">",
"      Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy. A systematic review. Endocrinol Metab Clin North Am 2002; 31:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/21\">",
"      Haritoglou C, Gerss J, Sauerland C, et al. Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2009; 373:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/22\">",
"      Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/23\">",
"      L&ouml;vestam-Adrian M, Agardh CD, Torffvit O, Agardh E. Type 1 diabetes patients with severe non-proliferative retinopathy may benefit from panretinal photocoagulation. Acta Ophthalmol Scand 2003; 81:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/24\">",
"      PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/25\">",
"      PKC-DRS2 Group, Aiello LP, Davis MD, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006; 113:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/26\">",
"      Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981; 88:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/27\">",
"      Photocoagulation for proliferative diabetic retinopathy: a randomised controlled clinical trial using the xenon-arc. Diabetologia 1984; 26:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/28\">",
"      Hercules BL, Gayed II, Lucas SB, Jeacock J. Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three-year interim report of a randomised, controlled study using the argon laser. Br J Ophthalmol 1977; 61:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/29\">",
"      Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978; 85:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/30\">",
"      Kotoula MG, Koukoulis GN, Zintzaras E, et al. Metabolic control of diabetes is associated with an improved response of diabetic retinopathy to panretinal photocoagulation. Diabetes Care 2005; 28:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/31\">",
"      M&auml;ntyj&auml;rvi M. Colour vision and dark adaptation in diabetic patients after photocoagulation. Acta Ophthalmol (Copenh) 1989; 67:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/32\">",
"      Michels RG, Rice TA, Rice EF. Vitrectomy for diabetic vitreous hemorrhage. Am J Ophthalmol 1983; 95:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/33\">",
"      Peyman GA, Raichand M, Huamonte FU, et al. Vitrectomy in 125 eyes with diabetic vitreous haemorrhage. Br J Ophthalmol 1976; 60:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/34\">",
"      Mandelcorn MS, Blankenship G, Machemer R. Pars plana vitrectomy for the management of sever diabetic retinopathy. Am J Ophthalmol 1976; 81:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/35\">",
"      Barrie T, Feretis E, Leaver P, McLeod D. Closed microsurgery for diabetic traction macular detachment. Br J Ophthalmol 1982; 66:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/36\">",
"      Williams DF, Williams GA, Hartz A, et al. Results of vitrectomy for diabetic traction retinal detachments using the en bloc excision technique. Ophthalmology 1989; 96:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/37\">",
"      Rice TA, Michels RG, Rice EF. Vitrectomy for diabetic traction retinal detachment involving the macula. Am J Ophthalmol 1983; 95:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/38\">",
"      Tolentino FI, Freeman HM, Tolentino FL. Closed vitrectomy in the management of diabetic traction retinal detachment. Ophthalmology 1980; 87:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/39\">",
"      Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988; 95:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/40\">",
"      Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990; 108:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/41\">",
"      Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch Ophthalmol 1985; 103:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/42\">",
"      Bhavsar AR. Diabetic retinopathy: the latest in current management. Retina 2006; 26:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/43\">",
"      Hirata A, Takano A, Inomata Y, et al. Plasmin-assisted vitrectomy for management of proliferative membrane in proliferative diabetic retinopathy: a pilot study. Retina 2007; 27:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/44\">",
"      Harhaj NS, Felinski EA, Wolpert EB, et al. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006; 47:5106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/45\">",
"      Ng EW, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci 2006; 1082:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/46\">",
"      Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/47\">",
"      Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113:1695.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/48\">",
"      Bakri SJ, Donaldson MJ, Link TP. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye (Lond) 2006; 20:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/49\">",
"      Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/50\">",
"      Friedlander SM, Welch RM. Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection. Arch Ophthalmol 2006; 124:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/51\">",
"      Isaacs TW, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 2006; 34:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/52\">",
"      Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006; 26:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/53\">",
"      Mason JO 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/54\">",
"      Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/55\">",
"      Minnella AM, Savastano CM, Ziccardi L, et al. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol 2008; 86:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/56\">",
"      Arevalo, JF, Wu, L, Sanchez, JG, et al. Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2009; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/57\">",
"      Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/58\">",
"      Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008; 18:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/59\">",
"      Gonz&aacute;lez VH, Giuliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol 2009; 93:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/60\">",
"      Ishikawa, K, Honda, S, Tsukahara, Y, Negi, A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 2009; 23:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/61\">",
"      Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2011; :CD008214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/62\">",
"      Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011; 95:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/63\">",
"      Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007; 18:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/64\">",
"      Jonas JB, Hayler JK, S&ouml;fker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/65\">",
"      Karacorlu M, Ozdemir H, Karacorlu S, Alacali N. Regression of optic nerve head neovascularization in proliferative diabetic retinopathy after intravitreal triamcinolone. Regression of diabetic optic disc neovascularization after intravitreal triamcinolone. Int Ophthalmol 2004; 25:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/66\">",
"      Bandello F, Polito A, Pognuz DR, et al. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006; 124:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/67\">",
"      Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol 2007; 39:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/68\">",
"      Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/69\">",
"      Salam A, DaCosta J, Sivaprasad S. Anti-vascular endothelial growth factor agents for diabetic maculopathy. Br J Ophthalmol 2010; 94:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/70\">",
"      Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/71\">",
"      Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/72\">",
"      Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/73\">",
"      Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/74\">",
"      Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33:2399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/75\">",
"      Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/76\">",
"      Nguyen QD, Shah SM, Heier JS, et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009; 116:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/77\">",
"      Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010; 117:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/78\">",
"      Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol 2012; 96:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/79\">",
"      Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/80\">",
"      Wang H, Sun X, Liu K, Xu X. Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. Curr Eye Res 2012; 37:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/81\">",
"      Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2012; 12:CD007419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/82\">",
"      Wu L, Mart&iacute;nez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/83\">",
"      Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol 2011; 152:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/84\">",
"      Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 2005; 139:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/85\">",
"      Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/86\">",
"      Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/87\">",
"      Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/88\">",
"      Lam DS, Chan CK, Mohamed S, et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007; 91:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/89\">",
"      Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/90\">",
"      Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/91\">",
"      Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 2006; 124:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/92\">",
"      Maia OO Jr, Takahashi BS, Costa RA, et al. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am J Ophthalmol 2009; 147:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/93\">",
"      Lam DS, Chan CK, Mohamed S, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology 2007; 114:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/94\">",
"      Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/95\">",
"      Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008; 92:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/96\">",
"      Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008; 145:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/97\">",
"      Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/98\">",
"      PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007; 125:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/99\">",
"      Kralinger MT, Pedri M, Kralinger F, et al. Long-term outcome after vitrectomy for diabetic macular edema. Ophthalmologica 2006; 220:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/100\">",
"      Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 2004; 242:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/101\">",
"      Stolba U, Binder S, Gruber D, et al. Vitrectomy for persistent diffuse diabetic macular edema. Am J Ophthalmol 2005; 140:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/102\">",
"      Yanyali A, Nohutcu AF, Horozoglu F, Celik E. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol 2005; 139:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/103\">",
"      Cho M, D'Amico DJ. Transconjunctival 25-gauge pars plana vitrectomy and internal limiting membrane peeling for chronic macular edema. Clin Ophthalmol 2012; 6:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/38/32362/abstract/104\">",
"      Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 1995; 18:631.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1773 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-218.189.88.190-9543B823DE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32362=[""].join("\n");
var outline_f31_38_32362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL MEASURES TO REDUCE RISK AND PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Is angiotensin inhibition preferred?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lipid lowering therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Multifactorial risk reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other preventive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT OF NPDR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT OF PDR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Panretinal photocoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vitrectomy for PDR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Medical vitrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - VEGF inhibitors for PDR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Intravitreal glucocorticoids for PDR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT OF DIABETIC MACULAR EDEMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Focal laser photocoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - VEGF inhibitors for ME",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3693387\">",
"      - Intravitreal glucocorticoids for ME",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - VEGF inhibitors versus IVTA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6681989\">",
"      Vitrectomy for CSME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Lifestyle measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Nonproliferative DR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Proliferative DR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Diabetic macular edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1773|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/33/30224\" title=\"diagnostic image 1\">",
"      Diabetic macular edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1773|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/45/25309\" title=\"figure 1\">",
"      Retinopathy and duration of DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/55/43901\" title=\"figure 2\">",
"      Retinopathy and HbA1c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/32/29197\" title=\"figure 3\">",
"      Strict glycemic control slows progression of retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/34/24109\" title=\"figure 4\">",
"      Treatment of severe retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/1/15379\" title=\"figure 5\">",
"      Focal photocoag for Tx ME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/24/17805\" title=\"figure 6\">",
"      Treatment of macular edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1773|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/26/33185\" title=\"picture 1\">",
"      Laser PRP for severe PDR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/51/28479\" title=\"picture 2\">",
"      Vitreous hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/54/40800\" title=\"picture 3\">",
"      Traction retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1773|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/18/17707\" title=\"table 1\">",
"      ADA opthalmologic exam schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/22/39276\" title=\"table 2\">",
"      Classification of DR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/7/41085\" title=\"table 3\">",
"      Treatment of DR",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/29/26074?source=related_link\">",
"      Age-related macular degeneration: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/13000?source=related_link\">",
"      Aldose reductase inhibitors in the prevention of diabetic complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/44/7881?source=related_link\">",
"      Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) therapy in patients at high risk for ocular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=related_link\">",
"      Classification and clinical features of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=related_link\">",
"      Pathogenesis of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/21/44369?source=related_link\">",
"      Patient information: Detached retina (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/34/11810?source=related_link\">",
"      Patient information: Diabetic retinopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39207?source=related_link\">",
"      Protein kinase C and the vascular complications of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42501?source=related_link\">",
"      Screening for diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_38_32363="Prevalence of syncope II";
var content_f31_38_32363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of syncope in Framingham cohort",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Prevalence,",
"percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"1\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac",
"       </td>",
"       <td>",
"        13.2",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke or transient ischemic attack",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizure disorder",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasovagal",
"       </td>",
"       <td>",
"        19.8",
"       </td>",
"       <td>",
"        22.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orthostatic hypotension",
"       </td>",
"       <td>",
"        8.6",
"       </td>",
"       <td>",
"        9.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medication",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"       <td>",
"        7.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        31.0",
"       </td>",
"       <td>",
"        40.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Includes data from 727 patients.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Soteriades ES, Evans JC, Larson MG, et al. N Engl J Med 2002; 347:878.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32363=[""].join("\n");
var outline_f31_38_32363=null;
var title_f31_38_32364="Differential diagnosis of seizures";
var content_f31_38_32364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Imitators of epilepsy: Nonepileptic paroxysmal disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neonates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jitteriness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign neonatal sleep myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperkplexia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breath-holding spells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign myoclonus of infancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shuddering attacks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sandifer syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign torticollis in infancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal eye movements (eg, spasmus nutans, opsoclonus-myoclonus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhythmic movement disorder (head banging)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breath-holding spells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasovagal syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migraine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign paroxysmal vertigo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staring spells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tic disorders and Stereotypies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhythmic movement disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasomnias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adolescents and young adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasovagal syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Narcolepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periodic limb movements of sleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sleep starts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paroxysmal dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemifacial spasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stiff person syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migraine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychogenic nonepileptic pseudoseizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hallucinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Older adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiogenic syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient ischemic attack",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drop attacks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transient global amnesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delirium or Toxic-metabolic encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapid eye movement sleep disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32364=[""].join("\n");
var outline_f31_38_32364=null;
var title_f31_38_32365="Effect of carboxyhemoglobin";
var content_f31_38_32365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of carboxyhemoglobin on measured oxygen saturation by pulse oximetry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 293px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    SpO",
"    <sub>",
"     2",
"    </sub>",
"    and cooximetry versus carboxyhemoglobin (COHb) at FiO",
"    <sub>",
"     2",
"    </sub>",
"    = 1.0. SpO",
"    <sub>",
"     2",
"    </sub>",
"    consistently overestimates O",
"    <sub>",
"     2",
"    </sub>",
"    saturation in the presence of COHb. At COHb = 70 percent, SpO",
"    <sub>",
"     2",
"    </sub>",
"    is still roughly 90 percent, while oxyhemoglobin has fallen to 30 percent.",
"    <div class=\"footnotes\">",
"     FiO",
"     <sub>",
"      2",
"     </sub>",
"     : fraction of inspired oxygen; O",
"     <sub>",
"      2",
"     </sub>",
"     : oxygen; SpO",
"     <sub>",
"      2",
"     </sub>",
"     : standard pulse oximetry.",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Barker SJ, Tremper KK, Anesthesiology 1987; 66:677.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32365=[""].join("\n");
var outline_f31_38_32365=null;
var title_f31_38_32366="Lyme cases by year";
var content_f31_38_32366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Reported cases of Lyme disease by year - United States, 2001 to 2010",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 428px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * National Surveillance case definition revised in 2008 to include probable cases.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: United States Centers for Disease Control and Prevention. Reported cases of Lyme disease by year, United States, 1996-2010. Available at:",
"     <a href=\"file://www.cdc.gov/lyme/stats/chartstables/casesbyyear.html\" style=\"FONT-STYLE: italic\">",
"      file://www.cdc.gov/lyme/stats/chartstables/casesbyyear.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32366=[""].join("\n");
var outline_f31_38_32366=null;
var title_f31_38_32367="Alendronate steroid BMD";
var content_f31_38_32367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Benefit of alendronate in glucocorticoid-treated patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 361px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of alendronate (5 or 10 mg/day) or placebo on bone mineral density in 477 patients receiving an average daily dose of at least 7.5 mg of prednisone per day or its equivalent. The mean bone mineral density of the lumbar spine increased by 2.1 and 2.9 percent over 48 weeks in the patients receiving 5 and 10 mg of alendronate daily, respectively, while decreasing 0.4 percent in the placebo group (top left panel). Femoral neck, trochanter, and total body bone mineral density also increased significantly in the alendronate groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Saag, KG, Emkey, R, Schnitzer, TJ, et al, N Engl J Med 1998; 339:292.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_38_32367=[""].join("\n");
var outline_f31_38_32367=null;
